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FROM THE RESIDENCY PROGRAM DIRECTOR
A Community of Scholars
The ideal of a University is that we live and work together as a
community of scholars dedicating ourselves to the
advancement of Medicine. Our community is at its best when
we share ideas, knowledge, perspective, and a passion for
Medicine. As a routine, this can occur at Morning Report or
Noon Conference, but also on rounds or hopefully at the
bedside when dealing with a particularly challenging case.
This journal serves as an outlet for observations or studies of
particular merit. Its publication is an important element of our
scholarly focus in the Department. Indeed, nearly a score of
contributors from all three classes of residents have
participated; making this issue quite representative of our
community. As a clinician and educator in the Department, I
have been regularly challenged by the spirit of inquiry among
our residents. This serves as a true reflection of the vitality of
our community.
Rounding in the MRICU during early November, I was also
struck by the incredible gift that we have been granted as
physicians in our society. During the span of one week, our

team which included Drs. Aleyas, Mehrotra, Callahan, Moon,
Cheskis, Nandi, and Levin faced a challenging array of
scholarly questions. These included identifying the cause for
interstitial pneumonitis in a pregnant woman, dealing with an
active TB patient from New Orleans who was refusing care,
and facilitating diagnosis for a patient with diffuse
lymphadenopathy who was only willing to accept minimally
invasive diagnostic and therapeutic interventions. This
community of scholars in the ICU found answers rapidly,
defended their differential diagnoses, and pushed the limits of
medical knowledge to provide outstanding care. They did so
with compassion and respect. Their work, together with the
dedicated nurses and therapists of the MRICU defined a
University as no words could express.
The editors of this journal have sought to capture the
excitement and vitality of our work in the Department. They
deserve our gratitude for doing this while managing the
routine expectations of the residency. I thank them for
contributing to our community of scholarship and elevating
our work within this University.
Gregory C. Kane MD
Associate Professor of Medicine
Residency Program Director
Department of Medicine

FROM THE EDITORS
Welcome to the 7th Edition of the Jefferson Medicine
Forum! In this edition we have highlighted some of the
many interesting and diverse cases encountered by our
Internal Medicine students, residents, and fellows. Every
case is an opportunity to take what a small number of
people have learned and share it with the rest of the
Jefferson community. From the pedestrian Wolf-ParkinsonWhite syndrome to the esoteric Milk Alkali Syndrome, our

residents see it all. Every contributing author represented in
this edition has left a touch of their enthusiasm, curiosity,
and analytical skills in each report. We extend our
appreciation to all our colleagues who captured their
experiences in images and prose for us to share.
Betty Lim, MD
Andrew Rose, MD
Karl Kwok, MD
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AN 18-YEAR OLD MAN WITH FEVER AND HEADACHE
Amy Baranoski, MD
An 18-year-old man was transferred from an outside hospital for
evaluation of recent headache, fevers, and laboratory abnormalities.
The patient had a past medical history significant for attention
deficit hyperactivity disorder (ADHD) and had presented to an
outside hospital with complaints of fatigue, fever, and headache.
He described the headache as frontal, severe, and stabbing in nature
without associated neck stiffness, photophobia, or phonophobia.
He also reported fevers to 105ºF. He was evaluated one day after
the onset of symptoms at a local emergency room where a lumbar
puncture was performed. By report of the patient and his mother,
the lumbar puncture was negative and he was given a prescription
for ketorolac for his headache. The patient went home and
continued to have fevers and headache for which he was taking
acetaminophen and ketorolac. Two days after his initial discharge
from the emergency room he presented to another hospital
complaining of sharp epigastric pain without radiation in addition
to the headache and fevers. He denied nausea, vomiting, or melena.
Laboratory data at that time revealed a creatinine of 4.6 and mildly
elevated transaminases and the patient was transferred to this
hospital for further evaluation and management.
The patient denied chest pain, cough, dyspnea, sore throat, or
dysuria. He reported that he had noticed a “sweat rash” in his
groin a few weeks prior to his symptoms that went away after
persisting for several days. His past medical history was only
significant for ADHD. He denied surgical history. Family history
was significant for hypertension in both parents. He reported
occasional alcohol use. He had recently graduated from high
school and lived in a suburban neighborhood. He had been
working as a groundskeeper at an outdoor chlorinated pool. He
denied tick bites, recent travel, or sexual activity.
Prior to transfer to this hospital, he was given empiric antibiotic
treatment with doxycycline and ceftriaxone and was placed on
maintenance intravenous fluids, pantoprazole, and prophylactic
dose subcutaneous heparin. His only out-patient medication prior
to the onset of his symptoms was methylphenidate (Ritalin®).
The temperature was 97.4ºF, the pulse rate was 71, the blood
pressure was105/59, the respiratory rate was 14 and the oxygen
saturation was 98% on room air. On physical examination, the
patient appeared well. His pupils were equal and reactive. His
sclera were anicteric in contrast to a previous documented
examination. He had no oral lesions. The heart and lung
examination was unremarkable. He had a left subclavian central
venous catheter in place without erythema or fluctuance at the
insertion site. He had normal bowel sounds and his abdomen was
soft, mildly distended and non-tender to palpation with no
appreciated organomegaly or masses. He had no costovertebral
tenderness, lower extremity edema, or neck stiffness. Neurological
exam revealed no focal deficits with intact cranial nerves.
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The patient’s initial lumbar puncture results were a glucose of 69,
protein of 29, no red blood cells, and one white blood cell.
Urinalysis was positive for protein, blood, and bilirubin, with 1025 WBC per high-powered field (HPF), 5 RBC per HPF,
occasional WBC and granular casts. Arterial blood gas was
7.37/24/66/14/95% on 3 liters oxygen via nasal canula. Other
laboratory data collected after his transfer to this institution were
negative and included HIV, EBV antibody and PCR, CMV,
HSV, toxoplasmosis antibodies, lyme antigen, and hepatitis
serologies. Multiple sets of blood cultures were negative.
Complement levels were normal. Leptospirosis antibody was
pending during his hospitalization.
The patient’s electrocardiogram was normal except for diffuse T
wave flattening. His chest x-ray showed no infiltrate or effusion.
An echocardiogram was significant for mild mitral, tricuspid, and
pulmonary valvular regurgitation with an ejection fraction of
50%. A right upper quadrant ultrasound showed that his spleen
and liver were top normal in size, but was otherwise not
remarkable. A CT scan of his abdomen was only significant for a
distended stomach and multiple sub-centimeter lymph nodes.

Table 1. Intial Laboratory Data
Initial Tests
White blood cells
WBC
Neutrophils (segs)
Bands
PT
INR
PTT
Sodium
Potassium
Chloride
CO2
BUN
Creatinine
Glucose
AST
ALT
Alk phos
Total Bilirubin
Direct Bilirubin
Amylase
Lipase
Troponin I
Urine Drug Screen

Result
6.7
11.6 B/L
92%
5%
15.3 secs
1.4
35.0 secs
134 meq/L
4.3 meq/L
99 meq/L
21 meq/L
41 mg/dL
4.6 mg/dL
97 mg/dL
48 U/L (nl 0-37)
70 U/L (nl 0-40)
193 U/L
8.3 mg/dL (nl 0.1-1.2)
4.7 mg/dL
159 U/L (nl 19-68)
77U/L (nl 16-63)
0.10 (nl <0.05)
Negative
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Doxycycline and ceftriaxone were continued during his hospitalization and he was given supportive treatment with intravenous
fluids. His creatinine and liver function tests improved upon
admission and returned to baseline values in several days. The
patient was discharged home on doxycycline with the presumptive
diagnosis of leptospirosis.
After discharge to home, the patient’s leptospirosis antibody level
came back at 12,800 (Negative <50, borderline 50-100, positive
>100). This patient was seen for follow up one month after
discharge and was feeling well.

Discussion
Leptospirosis is an illness caused by the organism Leptospira
interrogans. This is an aerobic spirochete with 18 or more coils
per cell. This organism is usually found in tropical environments,
but has a world-wide distribution. The highest incidence of illness
is after large precipitation events. The organism is found in
mammals; most commonly rodents, cattle, goats, horses, or dogs.
Animals can become asymptomatic reservoirs with bacterial
shedding in the urine. The organism can survive weeks to months
in soil and water. The most common mode of transmission in
humans is secondary to exposure to contaminated urine via mucus
membranes, conjunctiva, or damaged skin. The leptospires then
travel in the bloodstream and are carried to multiple organs, where
there is endothelial cell disruption leading to vasculitis and
ultimately, organ dysfunction.
The largest risk for exposure to leptospirosis is occupational and
includes farmers, ranchers, sewer workers, and military personnel.
There is also a risk through recreational exposure such as
freshwater swimming and kayaking. In 1998, an outbreak
occurred in Illinois among triathlon participants. People can also
be infected through pets, rodent exposure, and living in
contaminated rainwater catchment areas.
Leptospirosis can generally be divided into two groups. 90% of
patients have a mild, self-limited illness. The severe form of
leptospirosis is also known as Weil’s Disease. It is characterized by
hepatic and renal failure. These patients can also have pulmonary
hemorrhage, ARDS, and cardiac arrhythmias. EKG changes can
vary from frequent premature ventricular contractions to atrial
fibrillation or flutter, or even ventricular tachycardia. The
mortality rate in Weil’s Disease ranges from 5-40%.
The illness is characterized by abrupt onset of fevers, headache,
and myalgias in the majority of patients. There is usually an acute
phase which is a one to three day period of constitutional
symptoms. The immune phase then follows. There is a two to
thirty day incubation period before onset of symptoms.
Approximately 50% of patients have nausea, vomiting, and
diarrhea. Less than a third of infected patients have develop a nonproductive cough. Conjunctival suffusion is present in >80% of
patient with leptospirosis and should cause a high suspicion for
the disease if present. Less common symptoms include arthralgias,

bone pain, sore throat, and abdominal pain. Muscle tenderness,
especially in the calf and lumbar regions, may be present. Less
than 10% of patients develop a pretibial maculo-papular rash.
Other less specific signs such as lymphadenopathy, hepatomegaly,
or splenomegaly may be present. Aseptic meningitis is usually not
seen in acute illness but may occur in up to 80% of patients later
in the course of illness. The aseptic meningitis is secondary to an
immune reaction and not caused by the organism itself.
The laboratory data in leptospirosis is non-specific. The WBC
count is generally less than 10,000 B/L. Patient may have mildly
elevated transaminases, which are usually less than 200 U/L.
Urinalysis reveals mild proteinuria and more than 5 WBC per
HPF. Patient may have hematuria or hyaline casts. Cerebrospinal
fluid is also non-specific with normal glucose, protein between 50100 and cell counts less than 500. It is possible to grow leptospires
in CSF, blood, or urine, especially if cultured during the first seven
to ten days of infection. This is a fastidious organism which usually
takes one to two weeks to grow, but can take up to three months
in some cases. The organism requires Fletcher’s, Ellinghausen’s, or
polysorbate 80 media in order to grow.
Darkfield microscopy will show spirochetes and can be used to
make a presumptive diagnosis. PCR can also be used to diagnose
leptospirosis. In addition, there are indirect methods of detection
including microscopic agglutination test (MAT), which is a highly
sensitive and specific test for leptospirosis antibodies. MAT also
provides serotype specific information. There are also ELISA and
indirect hemaglutinin assays available. These tests do not provide
serotype information.
Mild disease can be treated with doxycycline 100 mg PO bid,
ampicillin 500-750 mg PO every six hours, or amoxicillin 500
mg PO every six hours. Moderate to severe disease requires
intravenous treatment with penicillin G 1.5 million units every 6
hours or ampicillin 0.5-1 gm every 6 hours.
Leptospirosis can be prevented by immunization of livestock and
pets. High-risk workers should wear protective clothing including
impermeable boots and gloves. Rodent control is also very important
in preventing outbreaks, especially after heavy rains. The CDC
recommends chemoprophylaxis for people at increased risk with
doxycycline 200 mg weekly beginning 1-2 days before exposure. ■
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PRESENCE OF CONCOMITANT ASYMPTOMATIC AND SYMPTOMATIC EMBOLI
RESULTING FROM ACUTE STAPHYLOCOCCUS AUREUS ENDOCARDITIS
Jason T. Bradley, MD, Nicole M. Orr, MD, and Siva Ramachandran, MD
A 25-year-old male intravenous heroin user with Hepatitis C
presented with a syncopal episode and left sided weakness.
Examination revealed sub-conjunctival hemorrhages and diffuse
bilateral petechiae on his lower extremities. He had multiple irregular,
erythematous, painless macules on his hands and feet, and linear, red,
subungal lesions bilaterally. These findings were consistent with
Janeway lesions and splinter hemorrhages, respectively. His vital signs
were stable on admission. Cardiac auscultation revealed a grade 2/6
holosystolic apical murmur radiating to the axilla. A brain MRI
revealed multiple areas of hyperdensity, particularly in the right
parietal lobe (Figure 1). Blood tests revealed leukocytosis and six of
six blood cultures yielded methicillin sensitive Staphylococcus Aureus.
The patient was treated with intravenous nafcillin and gentamicin.
One week later the patient’s neurologic status improved. A
transesophageal echocardiogram was performed and revealed both a
vegetation on the posterior leaflet of an otherwise normal mitral valve
and moderate mitral regurgitation. The following day, the patient
developed diarrhea that was positive for both heme and Clostridium
difficile toxin. Metronidazole was started and an abdominal CT scan
was ordered (Figure 2). Although there was no corresponding clinical
presentation, imaging revealed bilateral renal infarcts, a splenic
infarct, and sigmoid thickening. The patient regained full neurologic
functioning within two weeks of initial presentation and was
discharged after a 6 week course of intravenous nafcillin. He is
currently awaiting a mitral valve replacement.
In the setting of presumed septic emboli to both the skin and brain
secondary to bacterial endocarditis, we were concerned that the heme
positive stools were the result of embolization to the mesenteric
arteries. Although the abdominal CT showed no evidence of bowel
infarction and sigmoid thickening is non-specific, the renal and splenic
infarcts were determined to be secondary to septic emboli. A previous
case of bacterial endocarditis with simultaneous multiple organ
involvement including the kidney, spleen, brain, skin, and intestines
has not been documented. This case demonstrates that in the setting
of diffuse symptomatic septic emboli, involvement of additional organ
systems is likely but may be missed due to absence of clinical findings.
Concomitant symptomatic emboli to more than one organ system
are rare according to the literature. It is interesting to note that
petechiae occur in only 20-40%, Osler nodes in only 10-25 % of
patients, and Janeway lesions in less than 10% of patients with
bacterial endocarditis. Splenic septic emboli in infective endocarditis
are a common finding and incidental splenic infarcts were found in
38% of 29 asymptomatic patients in one study.
Majumdar et al. found that 18% of 354 patients with infective
endocarditis had renal involvement and 45% of that subpopulation
was found to have localized renal infarction, making it the most
common renal lesion. The authors of that study acknowledge this
renal subpopulation does not represent all patients with endocarditis
but a prospective study to assess symptomatic and asymptomatic renal
involvement has not yet been done.
The incidence of septic emboli to the brain has been well documented.
Whether or not embolization is a result of vegetation size is currently
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Figure 1. MRI of the
brain identifying multiple
areas of septic emboli.
Figure 2. CT of the Abdomen identifying
multiple embolic infarcts of the spleen (S)
and bilateral kidneys (Rk, Lk).
disputed, but current data suggest that vegetations greater than one
centimeter in length have increased risk for cerebral embolism4. Brain
embolization has been previously described in a case report and several
studies5,6, but not with concomitant lesions to other organ systems.
Eighteen percent of patients with mitral valve endocarditis develop
stroke and in over one-half of these cases, stroke was the initial
presenting symptom5. The authors concluded that all patients with
endocarditis and neurologic symptoms should undergo neurologic
imaging to determine the exact location of the lesions. Bakshi et al.
even concluded that neuroimaging should be used to diagnose
bacterial endocarditis in patients presenting with neurologic symptoms
and nonspecific constitutional symptoms. In addition, that study cites
that 50% of patients with neurologic sequelae of bacterial endocarditis
do not have clinical evidence of additional peripheral emboli.
In conclusion, although the patient was admitted for symptomatic
emboli to the skin and brain, non-symptomatic emboli to the kidney,
spleen, and intestine were incidentally found. It is well known that
infective endocarditis can infect the spleen, kidney, and brain, but
normally such emboli are symptomatic and isolated. This case
demonstrates that asymptomatic lesions may also be present in the
face of already existing symptomatic emboli and careful investigation
of critical organ systems should be done empirically.
■
The authors encountered this case during their time with the Department
of Pulmonary and Critical Care at Hahnemann University Hospital,
Philadelphia, PA.
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A 32 YEAR OLD MAN WITH LOSS OF CONSCIOUSNESS
Dana Critchell, MD
A 32-year-old man with no past medical history presented to the
emergency department after losing consciousness at the end of a
half-marathon. The patient was in his usual state of good health
until the last mile of the marathon when he began to feel unsteady
on his feet and short of breath. At the end of the race, he collapsed
and was found unresponsive by EMS. The patient had no memory
of the subsequent events and could only recall waking up in the
emergency department feeling “numb” and “confused” several
hours later. The patient denied any palpitations, chest pain,
nausea, blurry vision, dizziness, urinary incontinence, or headache
before or after the event. Of note, he was running outside
approximately 3 to 4 times a week prior to this episode.
The temperature was 99.1ºF (37.3 ºC), the pulse rate was 154,
and the blood pressure was 94/30.
On physical examination, the patient had regained consciousness,
but remained confused and disoriented with a GCS score of 13.
The patient was pale and diaphoretic, however he had moist
mucous membranes and no evidence of skin tenting. His pupils
were equal and reactive and the sclerae were anicteric. The heart,
lungs, abdomen, and extremity examination were unremarkable.
He had no costovertebral tenderness, lower extremity edema, or
neck stiffness. Neurological exam revealed no focal deficits with
intact cranial nerves. Several hours later, the patient was noted to
be alert and oriented to person, place, and time. In the interim,
the patient had several episodes of watery vomit.
Laboratory results on admission were notable for a normal CBC
with a platelet count of 225 B/L and a normal coagulation profile.
The creatinine was 2.4 mg/dL, the myoglobin was 303 ng/mL,
the CK was 157 IU, and the troponin was 0.15 ng/mL.
Electrocardiogram on admission revealed sinus tachycardia with
an isolated ST elevation in AVR and ST depressions in II and V4V6. A repeat electrocardiogram showed resolution of these
abnormalities. A chest x-ray and head CT scan showed no
abnormalities. The patient was fluid resuscitated with normal
saline at 200 cc/hr and admitted to the hospital with the diagnosis
of heat exhaustion and rhabdomyolysis with acute renal failure.
During his hospital stay, the troponin peaked at 0.54 ng/mL and
his creatinine dropped to 1.6 mg/dL with fluids resuscitation, and
plans were made to discharge the patient the following morning.
However, a CBC the following morning revealed marked
thrombocytopenia with a platelet count of 64 B/L and the CK
levels were now significantly elevated at 7105 IU. The patient
remained in the hospital to monitor his platelet count, which rose
to 97 B/L the following day. The patient was then discharged with
instructions for a follow-up CBC with his primary care provider
in the near future. Interestingly, another participant in the halfmarathon presented with acute renal failure followed by thrombocytopenia to 80 B/L the day after presentation.

Discussion
Heat exhaustion represents only one part of a continuum of heatrelated illnesses, ranging from heat stress to heat exhaustion to heat
stroke. While heat stress is simply perceived discomfort in a hot
environment, typically during physical exertion, heat exhaustion is
a more severe form of heat stress secondary to water or salt depletion
from excessive heat. Patients start becoming symptomatic at this
point, with many experiencing dizziness, weakness, extreme thirst,
headache or syncope. More serious manifestations, such as delirium
and seizures, are notably absent. Body temperatures can vary
anywhere from 37 to 40ºC. Once core body temperatures rise above
approximately 40ºC, patients begin to develop heat stroke, the most
virulent form of the heat-related illnesses.
Heat stroke requires two findings for its diagnosis, namely a core
body temperature greater than approximately 40 ºC and central
nervous system dysfunction, whether it be convulsions, coma,
delirium, or simple confusion.1 While heat stress and exhaustion
are typically considered relatively benign conditions, heat stroke
is a true medical emergency with mortality rates ranging from
20% to 70% depending on patient age. Its pathogenesis and
potential lethality are thought to be due to a combination of the
direct cytotoxic effects of heat, the physiological demands this
heat places on the body, and the host’s inflammatory and
coagulation response.1
Two types of heat stroke are described, one being classic heat
stroke and the other, exertional heat stroke. Classic heat stroke is
typically seen in those at the extremes of age and also in those
with underlying medical illnesses, including certain cardiovascular, neurological and psychiatric disorders. In addition,
individuals on certain medications such as diuretics or
anticholinergic agents are at an increased risk. Exertional heat
stroke, on the other hand, often affects young, healthy individuals
engaged in strenuous activity during times of high heat and
humidity. Interestingly, testing on some of these patients reveals a
susceptibility to malignant hyperthermia which may predispose
them to the development of heat stroke.
Despite this patient’s modest temperature elevation and moderate
physical stressor given his history of regular physical exercise, this
patient appeared to suffer from many of the more serious sequelae
classically seen only with heat stroke, including a change in mental
status, myocardial stress, rhabdomyolysis, acute renal failure and
thrombocytopenia. Neurologic dysfunction, whether secondary
to metabolic derangements, edema, infarction, or hypernatremia,
is, by definition, seen in all cases of heat stroke. While some
patients have gross neurological disturbances such as coma or
encephalopathy, other patients present with more subtle signs
such as inappropriate behavior or impairment in judgment.1
Unfortunately, patients often do not recover fully from these
neurological insults. One study found that 33% of patients who
presented with heat stroke and survived during the 1995 Chicago
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heat wave suffered long-term moderate to severe functional
neurological impairment.
Other potential complications of heat stroke involve virtually any
organ system and can rapidly lead to multi-organ dysfunction and
death even with proper supportive measures. Among these
complications are acute respiratory distress syndrome, myocardial
or hepatocellular injury, rhabdomyolysis, and acute renal failure.
Also commonly seen in heat stroke are bleeding diatheses, most
notably disseminated intravascular coagulation and isolated
thrombocytopenia.
One proposed theory behind the phenomenon of DIC in heat
stroke involves the splanchnic vasoconstriction and peripheral
vasodilation that occurs as part of the body’s compensatory
mechanisms after exposure to extreme heat. This vasoconstriction
can lead to intestinal ischemia and oxidative stress, resulting in
loss of the protective gastrointestinal barrier and leakage of
endotoxins into the systemic circulation. In addition, heat shock
itself induces an acute-phase response to help protect the body
from tissue injury. Inflammatory and anti-inflammatory
cytokines, most notably interleukin-1 and 6, TNF-alpha and
interferon-alpha, are elevated in heat shock, which contributes to
the thermoregulatory failure and circulatory shock not only
directly but also via increased production of nitric oxide which
further promotes intestinal permeability.1
Researchers have found that thrombocytopenia can also develop in
heat stroke in the absence of DIC. Furthermore, one case report
detailed a patient very similar to our patient with heat exhaustion
who presented with thrombocytopenia as well as leukopenia, both
presumably secondary to thermolysis. Thus, the hemostatic changes
in heat stroke are likely multifactorial in nature, a combination of
DIC, thrombocytopenia independent of DIC, and failure of
coagulation factor production secondary to hepatic injury.7
Treatment of heat stroke focuses on mainly on rapid cooling and
support of organ systems. Various cooling techniques can be
employed since no specific method has been shown to be superior.
Common methods include whole body immersion or the use of
fans to aid in conductive heat losses with cold water or ice to the
skin. Regardless, achieving a rectal temperature of 39.4ºC or less
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within thirty minutes of presentation has been shown to improve
survival. As of yet, there appears to be no role for medications such
as dantrolene, and the use of anti-pyretics has not been evaluated
thus far. Unfortunately, prompt cooling may not prevent the
development of tissue injury, patients should continue to be
observed even after stabilization and resolution of hyperthermia.1
This case is unique in that despite his diagnosis of heat exhaustion,
this patient developed several complications that typically occur
with the more deadly form of heat-related illnesses, heat stroke.
In addition, the dramatic fall in his platelet count highlights not
only the potential virulence of heat stroke but also, its
pathogenesis. In summary, due to a combination of heat toxicity
itself and a breakdown of the gastrointestinal barrier with
production of inflammatory cytokines, patients with heat stroke
and even heat exhaustion are vulnerable to thrombocytopenia
isolated from or in conjunction with DIC. As such, even after
hyperthermia has resolved, one should remain vigilant of this
potential complication, as well as many others, in all patients who
present along the continuum of heat-related illnesses.
■
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41 YEAR OLD WOMAN WITH FEVERS AND SHORTNESS OF BREATH
Jonathan Jun, MD
complicated by secondary bacterial
A 41 year-old African American female
pneumonia. Regardless, her case illustrates
with a history of asthma, hypertension, and
how quickly and severely a patient with
schizophrenia presented to the ER in
underlying lung disease (which probably was
February 2005 with shortness of breath,
more severe than she reported, given findings
wheezing, and a “wet-sounding” but nonof cor pulmonale and compensated
productive cough. She reported chills,
respiratory acidosis) can deteriorate when
subjective fever, rhinorrhea, and malaise for
infected with influenza. Clinical awareness is
five days prior. Her only medication was
paramount to timely diagnosis, prophylaxis,
albuterol, which she normally used twice
and effective treatment.
weekly as needed. She was never intubated
for asthma. On review of systems, she had
In the northern hemisphere, influenza
progressive dyspnea on exertion of less than
epidemics occur yearly from December to
two blocks for the last year. She denied
Figure 1. CT chest revealing hilar adenopathy
April. Normally the illness is most severe
night sweats, weight loss, or sick contacts,
in the elderly, very young, or those with
and right pleural effusion as well as consolidation.
HIV exposure, alcohol or drug abuse. She
chronic medical problems. Uncomplicated
admitted to smoking 1 pack per day for more than 15 years.
illness typically resolves within 1 week, but can progress to primary
influenza viral pneumonia or secondary bacterial pneumonia in
On physical exam, her temperature was 97.0 F, pulse 96 beats per
susceptible persons. The latter occurs as the virus denudes ciliated
minute, respirations 22 breaths per minute, blood pressure 130/100
epithelium, allowing bacterial entry into the lower respiratory tract.
mmHg. She had an oxygen saturation of 77% on room air which
Streptococcus pneumoniae, staphylococcus aureus, and Haemophilus
improved to 93% on 4 liters oxygen. She was an obese female in
influenza are the most common pathogens isolated in this setting.
moderate respiratory distress. Her orophaynx was clear. Her neck was
supple without thyromegaly or lymphadenopathy. Jugular venous
As was demonstrated in this case, serologic influenza tests, while
distension measured at 10 cm above the Angle of Louis. Heart exam
relatively sensitive and specific, do not generally yield data within a
revealed tachycardia without murmur, rub or gallop. Lungs had
clinically relevant time period. A diagnostic test should produce a
scattered rhonchi and wheezes bilaterally. Faint crackles were audible at
fourfold or greater rise in antibody titers between acute illness and
the bases. She had trace symmetrical ankle edema.
the convalescent phase approximately 10 days later. Our patient did
not have such a follow-up titer drawn, and diagnosis was based upon
Laboratory data on admission showed a WBC of 5900/L, (mostly
viral culture. Cultures could also be obtained by throat swabs, nasal
neutrophils and 30% lymphocytes) hemoglobin 14.7 g/dL, platelets
washes, or expectorated sputum. It takes 48 to 72 hours for the
142k/L. Chemistries were grossly normal except for a bicarbonate of
cytopathic effects of virus to appear in tissue culture. Rapid diagnostic
31 mmol/L. ABG on 4 L O2 showed pH 7.32, PCO2 of 31, PaO2
tests are also available. These include immunofluorescence (IF) assays,
71. LDH level was elevated at 687. Her coagulation indices, liver
enzyme immunoassays (EIA), and polymerase chain reaction (PCR)
function, cardiac enzymes, and urinalysis were within normal limits.
and yield results as early as 15 minutes to 2 days.
Chest X-ray showed a right lower-lobe consolidation and diffuse
infiltrates bilaterally. A chest CT further revealed hilar adenopathy and
In the United States, four medications are currently available for
a small right pleural effusion while excluding pulmonary embolism
treatment: amantadine, oseltamivir, rimantadine, and zanamivir.
(Figure 1). Blood cultures were sent, ceftriaxone and azithromycin were
Amantadine and rimantadine have activity against influenza type A,
administered, and serial nebulizer treatments were given for her asthma.
but not type B. Oseltamivir and zanamivir are neuraminidase
inhibitors with activity against both influenza A and B. If given within
The patient eventually became more hypoxic and was moved to the
48 hours of the onset of symptoms, these medications can reduce
ICU where she was intubated. Pressor agents were required for
symptoms, fever, and viral shedding by about 1 day. However, none
hypotension, and her degree of hypoxia required an FiO2 of 100%
of these medications is effective in preventing serious complications
with +15 of PEEP. On her subsequent chest radiographs, she
of influenza such as those seen in the case of this patient.
developed diffuse alveolar infiltrates in multiple areas consistent with
ARDS. Bronchoscopy and thoracentesis did not elicit any bacterial,
Current treatments for influenza can only benefit a select group of
fungal, or neoplastic etiology for her respiratory failure. Silver stain
patients who present early with uncomplicated disease. Therefore,
for PCP was negative. HIV serology was negative.
prophylaxic immunization in appropriate patients remains the most
effective means of controlling infection.
She remained intubated and on pressors for over 1 week. During
■
this time, admission influenza titers came back elevated for both
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Discussion
At first glance this case appeared to be one of bacterial pneumonia, sepsis
and ARDS. The lobar consolidation on her X-ray was more consistent
with bacterial pneumonia. Her septic hemodynamics also suggested a
bacterial infection (although influenza mimicking septic shock has been
reported in very young patients) Therefore, it is not clear if her critical
illness was due solely to influenza. More likely, she suffered from influenza
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A POST-PARTUM WOMAN WITH DYSPNEA
Saaron Laighold, MD
A G1P1 40 year-old Caucasian female without significant past
medical history presented to an outside hospital with worsening
shortness of breath and hemoptysis. The patient was 10 days
status post caesarian section for preeclampsia. Her course after
delivery was complicated by a stay in the ICU for shortness of
breath. She was discharged home 7 days post-delivery and then
returned to the hospital 3 days later. The patient was intubated at
the outside hospital for hypoxia (O2 sats of 50% on room air)
and transferred to TJUH for further management.
The patient’s family history was significant for her father being
deceased at age 40 from an MI and her mother being alive and
well. The patient lives at home with her husband and her child
who is healthy and well. She has no history of drug, alcohol, or
cigarette smoking.
Prior to delivery her medications included multivitamin, folate,
and ferrous sulfate. After delivery, the patient was discharged
home on metoprolol extended release 25 mg, furosemide, and
hydralazine. Upon transfer to TJUH she was on a dobutamine
drip, propofol drip, nitroglycerin drip, and intravenous enalapril.
The patient was transferred to the TJUH CCU already intubated
and sedated. Vitals signs were stable with temperature of 97.8F,
pulse of 105, respiratory rate of 19 and blood pressure of 143/78.
The physical exam was significant for jugular venous distension
to 15cm, presence of a third heart sound (S3), soft systolic ejection
murmur, bilateral coarse breath sounds, and 2+ lower extremity
edema to her knees.
Laboratory values including CBC, chemistry panel, cardiac
enzymes and electrolytes were normal at time of transfer. BNP
was 158, protein was 4.7 g/L, and albumin 2.9 g/L. Urinalysis
revealed 3+ blood and trace ketones while serum cortisol was 17.5
and TSH was 1.95 mIU/mL.
Studies at the outside hospital showed no pulmonary embolus on
CT scan of the chest and no deep vein thrombosis by lower
extremity dopplers. Echocardiogram revealed left ventricular
ejection fraction of 25-30% and moderate to severe mitral
regurgitation. Chest x-ray on arrival to TJUH was consistent with
pulmonary edema as shown below (Figure 1).
Differential diagnosis included peripartum cardiomyopathy,
accelerated hypertension, diastolic dysfunction, systemic
infection, pulmonary embolism, preeclampsia, amniotic fluid
embolus, or cardiomyopathy due to infection; ischemia; or
toxicity. The time course, clinical presentation, and studies helped
to narrow in on the etiology of her symptoms.
The patient presented 10 days post-partum with signs of left-sided
congestive heart failure with a decreased ejection fraction on her
echocardiogram. The fact that the patient presented in the postpartum period rather than earlier in her pregnancy would seem to
eliminate an underlying cardiomyopathy. Her echocardiogram
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revealed systolic dysfunction making diastolic dysfunction
unlikely to be the cause for this woman’s symptoms. She was ruled
out for a pulmonary embolus and did not have any signs of
systemic infections or indications of an underlying ischemia to
account for the new onset cardiomyopathy.
Amniotic fluid embolism can cause hypoxia in the post-partum
period. However, the onset of symptoms typically presents during
labor and delivery or within the first 48 hours after delivery as
opposed to symptoms of severe hypoxia 10 days after delivery, as
was the case with this patient. Also, patients with amniotic fluid
embolism will typically present with disseminated intravascular
coagulation and symptoms similar patients with anaphylactic or
septic shock.
Preeclampsia and accelerated hypertension were though to be
implausible causes in this case because the patient did not present
with severe hypertension at the time of her severe hypoxia. The
patient’s symptoms of preeclampsia should have improved after
delivery instead of causing her to become hypoxic 10 days post delivery.
The patient’s presentation was thought to be consistent with
peripartum cardiomyopathy. She was treated for congestive heart
failure with intravenous furosemide and ACE inhibitor along with
the dobutamine and nitrates. After several days of diuresis, a repeat
echocardiogram revealed mild to moderate mitral regurgitation,
moderate left atrium enlargement, and an ejection fraction of 4045% with mild global LV dysfunction. The patient was extubated
after several days and transferred to a telemetry floor. She
continued to improve with medical treatment for her heart failure.
The patient was discharged home on an ACE inhibitor, betablocker and diuretics with the recommendation that she avoid
future pregnancies.
The patient had several risk factors for the condition including
older maternal age and the development of preeclampsia during
her pregnancy. The improvement in symptoms and the
improvement in LVEF with supportive therapy were consistent
with a peripartum cardiomyopathy as opposed to other causes for
her presentation.

Discussion
Peripartum cardiomyopathy (PPCM) was first described in the
1700s and first defined in 1937. It is a rare form of dilated
cardiomyopathy of unknown etiology which affects women in
late pregnancy or early post-partum. The true incidence of this
condition is unknown but it is thought to be 1 per 3000 to 1 per
4000 live births or between 1000 and 1300 women each year in
the US. For unknown reasons, the incidence of PPCM is higher
in certain regions of the world. In one area of Haiti the incidence
is estimated to be 1 in 300 pregnancies.
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cocaine abese, nutritional deficiencies including Selenium, and long
term oral tocolytic therapy with Beta-agonists such as terbutaline.

Figure 1. CXR showing pulmonary edema.
Peripartum cardiomyopathy is defined by cardiac failure within
the last month of pregnancy or within 5 months postpartum. The
condition is characterized by the absence of other causes of
congestive heart failure and the lack of heart disease prior to the
last month of pregnancy. Most patients with PPCM present with
symptoms of congestive heart failure within the first 4 months
post-partum (78%). 9% of patients present in the last month
before delivery while 13% present more than 1 month antepartum
or more than 4 months postpartum. The time course for
peripartum cardiomyopathy contrasts with the time for
presentation of congestive heart failure due to other etiologies.
The 2nd trimester of pregnancy is the greatest hemodynamic
burden of gravid state and most patients with underlying cardiac
dysfunction tend to develop symptoms of heart failure at this
time. Normal pregnancy causes increased blood volume, increased
cardiac output and decreased afterload so that patients with
underlying cardiac disease present earlier during pregnancy than
patients with PPCM.

While the etiology of PPCM remains elusive, investigation of
women with PPCM and associated risk factors has led to identification of several possible etiologies. Viral myocarditis is one
suspected cause of PPCM. Studies have reported the incidence of
myocarditis among PPCM patients to be from 9% to 78%. Some
studies have estimated the incidence of myocarditis to be similar to
controls with idiopathic dilated cardiomyopathy while other studies
have estimated the incidence of myocarditis to be much higher
among patients with PPCM. The variation among study results is
thought to be due differences in the timing of myocardial biopsies
and due to variations in the definition of myocarditis used by
pathologists. Investigators have speculated that pregnancy may
increase patient susceptibility to viral myocarditis leading to PPCM.
It has been postulated that PPCM may be caused by an
autoimmune reaction. Supporting evidence for this theory
includes the finding that high titers of autoantibodies against
cardiac tissue proteins have been identified in women with
PPCM. The suspected autoimmune mechanism is that fetal cells
escape into the maternal circulation and take up residence in
cardiac tissue triggering an autoimmune reaction against the
myocardium. After delivery, it is theorized, the fetal cells in the
myocardium are recognized as nonself when the autoimmunosuppresion of pregnancy subsides and the patient’s immune
system attacks the cardiac myocytes causing cardiomyopathy.

Patients are judged to have PPCM after they present in congestive
heart failure within the last month of pregnancy or within the
first 5 months postpartum. By echo criteria, women with PPCM
have LVEF<45%, decreased fractional shortening<30%, and
end/diastolic dimension>2.7 cm/m3. Symptoms for congestive
heart failure in patients with peripartum cardiomyopathy are
similar to heart failure symptoms for patients with other etiologies
of CHF. Symptoms include dyspnea, orthopnea, PND, MR
murmur. Physical exam signs include cardiomegaly, S3, JVD,
peripepheral edema, arrhythmias, and pulmonary rales.

Other theories for the etiology of PPCM include systemic
inflammation, hormonal involvement and nutritional
deficiencies. Inflammation is believed to be involved in the
pathogenesis of PPCM as it does in other etiologies of CHF.
TNF-alpha, IL-6, Fas/APO-1 are significantly elevated in patients
with PPCM compared to controls. FAS: apoptosis-signaling
receptor is significantly elevated in patients who died from PPCM
as compared to controls. Relaxin is an ovarian hormone produced
during pregnancy which is thought to play a role in PPCM.
Relaxin has positive inotropic and chonotropic properties and
abnormalities of this hormone are speculated to participate in the
pathogenesis of PPCM. Nutritional deficiencies, especially
selenium deficiency have been found among women with PPCM.
In one area of Haiti where PPCM is exceptionally common
pregnant women commonly suffer from nutritional deficiencies.
Selenium deficiency may play a role in the pathogenesis of PPCM
because it may make the heart more susceptible to injury from
viruses, hypertension, or hypocalcemia.

While the cause of peripartum cardiomyopathy remains unknown
a number of risk factors are associated with the development of the
condition. Risk factors include age greater than 30 years,
multiparity, women of African descent, pregnancy with multiple
fetuses, history of preeclampsia, eclampsia, postpartum HTN,

Therapy for PPCM involves standard heart failure management
including diuretics, inotropes, and blood pressure control.
Management of PPCM in the antepartum period must account
for possible teratogenecity of certain medications typically used
for heart failure patients. ACE inhibitors are contraindicated in
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pregnancy and so they should be avoided. Hydralazine and
nitrates are safer to use for blood pressure therapy. Similarly,
anticoagulation to prevent the risk of embolism formation should
avoid coumadin in the antepartum period because of its possible
teratogenecity. Both heparin and coumadin should be safe to use
postpartum because neither are excreted into breast milk. If the
diagnosis of PPCM is made in the antepartum period, delivery
should be strongly considered because of the risk of continuing
the pregnancy to both the fetus and the mother.
PPCM has a high incidence of serious morbidity and mortality
with listed mortality rates between 18% and 56%. Complications
from PPCM include arrhythmias, progressive heart failure
necessitating BiV pacemaker and defibrillator implantation or
heart transplant, and thromboembolism. Clot formation is an
important complication with an incidence which has been reported
to be as high as 50%. The high frequency of thromboembolism is
due to the hypercoaguable state of late pregnancy, stasis and
turbulent blood flow in dilated cardiomyopathy and the common
practice of placing patients in late pregnancy on bed rest.
The outcome for women with PPCM is extremely varied with
the serious consequences of the condition usually occurring in
the months following the diagnosis. In some patients with PPCM,
clinical and echocardiographic status improves quickly and returns
to normal. Other patients deteriorate rapidly necessitating device
implantation or transplantion. Still others, will respond to therapy
and have persistent signs of cardiac dysfunction. US mortality
ranges from 25% to 50% with close to 50% of deaths occurring
in the first 3 months postpartum.
Women who do recover usually do so within 6 months of the
diagnosis and a substantial number of affected women will have
significant improvement within the first 6 months. In one study,
50% of patients with PPCM had resolution of cardiomegaly and
LV dysfunction at 6 months after delivery without reported
cardiac mortality. Patients with persistent cardiac abnormalities at
6 months after delivery had a mean survival of 4.7 years and an
85% mortality at 5 years.

Left ventricular size and severity of left ventricular dysfunction are
related to worsening outcomes in the acute and subacute phase
following the development of PPCM. Poor outcome is associated
with worsening LV size and dysfunction, higher parity, being an
older patient, and later onset of symptoms following the pregnancy.
Future pregnancies for women with PPCM carry substantial risk.
Small studies have shown that women with PPCM have worse
outcomes in future pregnancies compared to normal patients even
if their left ventricular size and function has returned to normal.
Studies have shown worse outcomes for mother and fetus in
women with persistent LV dysfunction as compared to women
with PPCM who have regained normal function. In one NEJM
study, in women with PPCM who regained normal function 25%
of future pregnancies were associated with cardiac dysfunction. In
patients with persistent left ventricular dysfunction, 50% of
subsequent pregnancies were associated with worsening cardiac
dysfunction. Table 1 shows that women with PPCM had a high
incidence of maternal complications during subsequent pregnancy
with a higher incidence among those whose LV function had not
recovered from the initial pregnancy.
Fetal health has also been found to be worse among women with
PPCM in future pregnancies. In the NEJM study, of the women
who had regained normal function 13% of women delivered
prematurely. In women with continued left ventricular
dysfunction, 50% of pregnancies ended in premature births and
25% of the patients required therapeutic abortions.
■
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34 YEAR OLD WOMAN WITH THROMBOCYTOPENIA AND WEAKNESS
M. Paula Martinez, MD and Ubaldo E. Martinez, MD
reticulocyte 2.2%, LDH 188 IU/L,
Patient is a 34 year old Liberian Female with
haptoglobin 115 mg/dL, total bilirrubin 0.5
past medical history significant for Systemic
mg/dL, creatinine 0.5 mg/dL. INR 1.21, PT
Lupus Erythematosus (SLE) that was
15.8 sec, PTT 27 sec. Fibrinogen 480
recently admitted to the hospital for
mg/dL, D-Dimer 6.49 mcg/ml. Peripheral
weakness and was diagnosed with
smear showed decreased platelets without
encephalomyelitis due to SLE. At that time
clumping and scarce schistocytes.
the patient was also noted to have low
platelets felt secondary to Immune
The patient’s blood smear was not
Thrombocytopenic Purpura (ITP). She has
consistent with TTP. ITP was felt to be the
history of thrombocytopenia with her four
most likely cause of her thrombocytopenia
pregnancies. During this past admission the
and she underwent treatment initially with
patient was treated with hydroxychloroquine
high dose steroids and subsequently with
and high dose steroids for the CNS
Figure 1. CT angiogram of chest with
IVIG, both without significant response.
involvement of SLE but no platelet response
finding of large splenic mass.
Her bone marrow biopsy showed
was noted with administration of steroids.
hyperplastic megakaryocytosis consistent
She was discharged to a rehabilitation facility, but returned to the
with peripheral destruction. She also underwent treatment with
hospital with a new episode of worsening weakness.
rituximab for encephalomyelitis without platelet response. A CT
Angiogram of chest was ordered during her hospitalization for an
On admission the patient was again noted to be thrombocyepisode of shortness of breath. There was no evidence of
topenic and anemic. She denied epistaxis, easy bruising, rash,
pulmonary embolism but a large heterogeneous splenic mass was
fatigue, fevers, chills, shortness of breath, or symptoms related to
visualized (Figure 1). This mass upon further evaluation with MRI
upper respiratory infection. Her only complaint on presentation
was hypervascular and the differential diagnosis included
was weakness in the upper and lower extremities that worsened
angiosarcoma and hemangioma.
over the last week.
Medications she was taking included prednisone, hydroxychloroquine, alendronate, calcium carbonate and pantoprazole. She
denied any drug allergies. Past medical history was significant for
SLE complicated with encephalomyelitis and questionable history
of ITP with exacerbations during pregnancy. Past psychiatric history
included possible conversion disorder. No previous surgeries were
noted. She denied any alcohol, tobacco, non-prescription
medications, herbal substances or illegal substance use. Patient had
previously worked with her husband in their restaurant, but was
currently on disability. She is married with 4 children.
Physical exam revealed she was afebrile with a blood pressure
120/66 mmHg, heart rate 79 beats per minute, respirations 12
breaths per minute, and 98% oxygen saturation on room air. She
was alert awake and oriented times three, pupils were equal, round
and reactive to light and extraocular muscle movements were
intact. Sclera was anicteric and no petechiae were noted on buccal
mucosa. No lymphadenopathy in cervical, axillary or inguinal
regions was appreciated. Lungs were clear and heart was regular
without murmurs to auscultation. Abdominal exam was benign
and there was no edema in the lower extremities. On neurological
exam, cranial nerves and cerebellar exam were within normal
limits. The patient had decreased strength in the upper and lower
extremities bilaterally, graded as 4/5 and 1/5 respectively. Deep
tendon reflexes were symmetrical and graded as 2/4 and plantar
reflex was down-going. On examination of the skin no rash,
petechiae or purpura were noted.
Her labs and studies were remarkable for hemoglobin of 10.8
g/dL, platelets 57000/microL, MCV 70fl, RDW 21.7%,

The patient underwent splenectomy and pathology revealed a
large splenic hemangioma with necrosis. Platelet counts steadily
rose from the day of splenectomy and remained stable during the
remainder of her hospitalization.

Discussion
This patient had thrombocytopenia from splenic sequestration
due to a large hemangioma. Hemangiomas are the most common
primary tumor of the spleen with a prevalence of 0.03-0.14%.
This is a congenital lesion arising from sinusoidal epithelium
resulting from proliferation of vascular channels lined by a single
layer of endothelium, most often resulting in a cavernous lesion.
Hemagiomas are variable in size ranging from a few millimeters
to several centimeters. The majority of these tumors are less than
4 cm, but there are reports of lesions up to 17 cm in diameter.
Hemangiomas may be single or multiple as in Klippel-TrenauneyWeber Syndrome.
The majority of hemangiomas are asymptomatic and incidentally
discovered. However, larger lesions may enlarge the spleen leading
to fullness and left upper quadrant discomfort, spontaneous splenic
rupture or Kasabach-Merritt phenomenon (thrombocytopenia
and/or coagulopathy, now called disseminated intravascular
coagulation or DIC, that results from platelet trapping within a
vascular tumor). Thrombocytopenia results from shortened platelet
survival caused by sequestration of platelets in the vascular
malformation. Episodes of acute DIC have been reported in
pregnant women with congenital hemangiomata and in one
woman during two successive pregnancies. The hormonal
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alterations and increase in blood volume in pregnancy may affect pre-existing lesions, triggering
episodes of acute DIC.
This patient presented with an uncommon cause of thrombocytopenia in the general
population. Our approach to the patient with decreased platelets should first be focused on
ruling out potential fatal causes such as TTP with the peripheral smear and pseudothrombocytopenia or clumping. In the differential diagnosis of low platelet counts one should also include
medications, alcohol abuse, viral infection, hypersplenism, disseminated intravascular
coagulation, myelodysplastic syndrome. ITP should be considered as a diagnosis of exclusion.
Common medications associated with thrombocytopenia include heparin, glycoprotein IIb/IIIa
inhibitors, diuretics, trimethoprim-sulfamethoxazole and quinine.
■
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LIVER TRANSPLANT RECIPIENT WITH BILATERAL LEG SWELLING
Kuntal M. Thaker, MD, Maya Spodik, MD, Kuldip S. Banwait, MD, Steven K. Herrine, MD, and Victor Navarro, MD
A 50-year-old white male was admitted to the hospital with
erythema and swelling of both lower extremities.
The patient had a medical history significant for liver transplant
five years prior for end-stage liver disease secondary to alcoholic
cirrhosis. Following transplant, he developed mitral valve
insufficiency with heart failure and pulmonary hypertension. He
had been in his usual state of health until approximately a week
prior to admission when he noticed that his lower extremities had
increased in girth. For several days, he noted that there had also
been increased redness and pain over the affected area.
The patient denied other symptoms such as headache,
photophobia, phonophobia, or weakness. He had no report of
dyspnea or a new productive cough. There was no other significant
past medical or surgical history. Prior to his initial diagnosis, his
alcohol consumption was difficult to quantify, however, since
several years prior to transplant, the patient had remained
abstinent. He had not traveled outside of the United States. His
immunosuppressive regimen consisted of prednisone 10mg and
sirolimus 1mg once a day and knew of no allergies to medications.
The vital signs were significant only for a temperature of 100.8ºF;
all other vital signs were normal.
On physical examination, the head, neck, heart, lungs, and
abdomen were normal. Multiple, irregularly-shaped, deep
ulcerations with surrounding erythema were seen on both lower
extremities. There was no evidence of necrosis, however, there was
significant edema of the lower extremities.
The patient was started on a regimen of broad-spectrum antibiotics
consisting of intravenous vancomycin and piperacillin/tazobactam
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for the treatment of cellulitis in an immunocompromised host.
Initially, there was no resolution of the cellulitis or ulceration.
Blood cultures remained persistently negative. Magnetic resonance
imaging of the lower extremities revealed cellulites of the right
lower extremity and myositis with fasciitis on the left.
Biopsy of the skin lesions revealed diffuse yeast forms with
mucicarmine positive capsules consistent with cryptococcus
infection. Cryptococcal antigen titer was markedly elevated at 1:251,
consistent with cryptococcus infection. Evaluation of cerebrospinal
fluid did not reveal meningeal involvement. The patient was started
on amphotericin B with complete resolution of the lesions.
Cutaneous involvement is an uncommon manifestation of
cryptococcal disease, but it may be the initial manifestation of
systemic cryptococcosis in solid-organ transplant (SOT) recipients
and other immunocompromised hosts. Only 36 cases have been
described in the literature and majority of them are in renal
transplant recipients. No cases of cellulitis with fasciitis and
myositis without systemic involvement have been described for
liver transplant patients. We describe a liver transplant recipient
diagnosed with cellulites, fasciitis, and myositis as the only
presenting manifestation of cryptococcal infection..
Cryptococcal infection must be included in the differential
diagnosis of cellulitis in SOT recipients. Deep soft tissue
involvement may occur concomitantly with primary cutaneous
cryptococcosis. Because the clinical appearance of cutaneous
cryptococcosis is non-specific, early diagnosis requires tissue
acquisition for testing. Tissue samples should be stained with the
fungal stain mucicarmine to reveal the characteristic organisms.
Cryptococcal antigen test is a simple blood test that may aid in
the diagnosis of cryptococcosis.
■
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55 YEAR OLD WOMAN WITH PNEUMONIA
Andra Popescu, MD
A 55 year old Caucasian female smoker, with past medical history
significant for hypertension and peptic ulcer disease presented to
the emergency department with a four day complaint of malaise,
fever, and myalgias. She was seen by her primary care physician
who started her on amoxicillin clavulanate for possible strep
throat infection. Her family reported a productive cough with
green sputum, pleuritic chest pain, nausea, vomiting and diarrhea
for one week. They also felt she was getting more confused over
the past several hours.
The patient was found to be confused, hypotensive, and hypoxic.
Temp 98.1F, heart rate 107 beats per minute, respiratory rate 16
breaths per minute, blood pressure 73/51 mmHg, and oxygenating
at 89% on room air. Physical exam revealed bilateral wheezing that
was more prominent in the right lung field. She was tachycardic
with no murmurs or rubs. The abdomen was soft and non-tender
with no organomegaly and she had no evidence of a rash.
Labs on admission: WBC 2,600/mm3, Hemoglobin 13.3 g/dL,
platelets 255,000/mm3, Na+ 134, K+ 4.5, HCO3- 19, BUN/Cr
49/2.8, AST 85, ALT 53. ABG: pH 7.2, PaCO2 49, PaO2 75,
O2 Sat 92%
The differential diagnoses at the time of presentation included
community acquired pneumonia with Streptococcus
pneumoniae, Haemophilus influenzae, and Moraxella catharalis
being high on the list of pathogens along with the atypical
organisms such as Legionella, Mycoplasma and Chlamydia.
Other infectious pathogens such as anaerobes and fungi are also
included. Non-infectious etiologies including pulmonary
embolism, vasculitis, hypersensitivity pneumonitis and neoplastic
lymphangitis spread were also considered.
The patient was admitted to the ICU with presumptive
admission diagnosis of septic shock secondary to pneumonia and
was intubated within 1 hour of admission due to hypoxic
respiratory failure requiring FIO2 100% and 16+ PEEP to
maintain PO2 of 70 mmHg. Stress dose steroids were started
empirically, as well as empiric antibiotic coverage with
azythromicin, pipericillin/tazobactam, and vancomycin.
Recombinant human activated protein C was also administered
12 hours after admission. Two days later urine legionella antigen
was found positive and antibiotics were switched to levofloxacin.
The patient required pressure support for ten days and was
extubated on the fifteenth day of hospitalization.

Epidemiology and clinical manifestations
First identified in 1976 during an outbreak at the annual meeting
of the American Legion in Philadelphia (where out of 221 people
infected, 34 died), Legionella is a facultative intracellular aerobic
gram negative rod producing beta-lactamase, hardly visible on
Gram stain due to its diminutive size. There are two major
presentations of Legionella infection; the first being Legionnaires’
Disease which is a community acquired pneumonia whose course
can become very dramatic and the second being Pontiac fever

Figure 1. Chest X-ray revealing dense alveolar opacity at the right
lung base with air bronchograms. There are left mid lung atelectatic
changes and significant central vascular pulmonary congestion.
which is a more benign and self limited disease manifested through
headaches, low grade fevers, malaise and chills without respiratory
complaints and no radiological x-ray findings. Pneumonia is the
most common clinical manifestation and Legionella has been
reported as the third or fourth most commonly identified
pathogen in community acquired pneumonias.1-2 However, it did
account for only 4.7% of the CAP cases in one large study.3 Its
prevalence is highlighted by the fact that it is also mentioned as
one of the most common pathogens identified in nosocomial
pneumonia.

Legionnaires’ Disease
With an incubation period of two to ten days, this pathogen is
considered transmitted through to the air conditioning and water
cooling systems, rather then transmitted from person to person.
Although first thought to manifest only as severe pneumonia
(second only to S. pneumoniae in organisms identified in ICU
admissions for pneumonia) accompanied by gastrointestinal
symptoms and high fevers4-6, current diagnostic testing proved
that presentation of Legionella infection may vary widely and that
symptoms may be nonspecific.
Among the clinical clues for diagnosis of Legionnaires’ disease are
the gastrointestinal symptoms, especially diarrhea; neurological
findings such as confusion, headache and lethargy; and fever >
390 C. Cough is usually mild and only slightly productive,
hemoptysis is rarely encountered, and chest pain is infrequent.
Physical exam is nonspecific with rales and subsequent signs of
consolidation, fever as high as 40° C, bradycardia, lethargy, and
stupor. Sputum gram stain shows WBC abundance but scant or
no microorganisms. Hyponatremia (Na+ often less than 130)1,5-6,8,
hepatic and renal dysfunction, hematuria, thrombocytopenia and
failure to respond to classic ß lactam antibiotic treatment are often
specifically seen in patients with Legionella. One should always
maintain a higher index of suspicion for Legionella infection in
patients considered at risk including smokers, those with chronic
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Figure 2. CT of the
chest showing dense
right lower lobe
consolidation, scattered
areas of groundglass
opacity and scattered
focal nodular densities.

lung disease, and immunosupressed patients such as those receiving
steroids or anti-rejection drugs for post-organ transplant.
Radiological findings are usually already present by the third day of
illness. Most commonly seen are patches consistent with unilobar
infiltrates which may progress to consolidation. Pleural effusion
may also be seen on x-ray, although infrequently9. In the immunosupressed host, densities may appear as round opacities at the lung
base, often progressing into cavitary lesions. Of note, radiological
changes usually lag behind the clinical course, with complete
resolution of the infiltrates within 4 weeks to several months from
the debut of the illness.
Although some clinical manifestions are distinctive for Legionella
infection, none of them are pathognomonic or highly specific.
Early detection with prompt and appropriate antibiotic treatment
have been proven to save lives10,11. Culturing for Legionella spp. is
the single most important laboratory test, but is time consuming
and requires adequate respiratory specimen and a special culture
media. Other tests have proved to be more beneficial: urinary
antigen testing is rapid, sensitive, specific, and not costly.
However, it is only useful for the diagnosis of L. pneumophila
type 1 infection (accounting for 90 percent of communityacquired Legionella infections in the United States). The
combination of culture of an appropriate respiratory specimen
and urinary antigen testing are optimal as a diagnostic approach.
Serologic tests, although available, are generally far less useful for
the diagnosis of an individual patient but very useful for large
epidemiological studies. While PCR-based tests exist, to date they
do not exceed the sensitivity of culturing the organism. Given the
severity and the high incidence of Legionella infection it is
reasonable to perform specific diagnostic tests for all patients
requiring hospitalization for community acquired pneumonia.

Treatment
The mortality of untreated or inadequately treated community
acquired Legionnaires’ disease is 16-30%, while the mortality for
the nosocomial Legionnaire’s disease may be as high as 50%12.
Timely use of the current diagnostic tests as well as prompt
antibiotic treatment with active drugs have decreased mortality to
less than 10%.
Although frequently used in the past, erythromycin has now been
supplanted by newer macrolides as well as respiratory tract

quinolones. Two studies13,14 showed the higher efficacy of levofloxacin
compared to macrolides as well as fewer complications and shorter
hospitalizations. Current recommendations are a 7-10 day course of
azithromycin or 10-14 day course of levofloxacin, with a longer 21
day course for immunosupressed patients and patients requiring
ICU admission. Given the high incidence and the severity of this
disease, current recommendation for community acquired
pneumonia requiring hospitalization is azithromycin either as
monotherapy or along with ß-lactame antibiotics15,16. Monotherapy
with an active quinolone is also acceptable. For nosocomial
pneumonia, a quinolone (ciprofloxacin or levofloxacin) is the
empiric drug of choice since the nosocomial infections are frequently
associated with gram negative bacilli. For endocarditis and other
extrapulmonary infections, a combination therapy is recommended
with levofloxacin or azithromycin plus rifampin. Despite a
significant decrease in mortality with prompt and proper antibiotic
treatment, patients often have residual symptoms 17 such as chronic
fatigue syndrome (75%) and residual neurological deficits (63%).
Our case patient finished 21-day course treatment with
levofloxacin for ARDS secondary to Legionnaires’ disease.
Hospital coursee was complicated by development of
quadriparesis thought to be secondary to ICU neuropathy. Of
note, Legionella Pneumophilla has also been linked independently
with quadraparetic complications. The patient did achieve further
improvement in her neurological status and was able to be
transferred to a rehabilitation facility.
■
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A 56-YEAR-OLD MAN WITH VERTIGO AND HYPERCALCEMIA
Veronica Rivera and Andrew Rose, MD
A 56-year-old Man with a past medical history significant for
lower back pain and GERD was admitted to the hospital for
dizziness and laboratory abnormalities.

revealed normal sphincter tone and an asymmetric nodule on the
left lobe approximately 1 cm in diameter. His neurologic exam
was non-focal and his cranial nerves were intact.

Five days prior to admission, the patient noted that he felt dizzy
and unsure while walking. These symptoms persisted without
change and he went to see his primary care doctor the day prior
to admission. The patient was given meclizine for his dizziness
and routine labs were drawn. He received a call from his doctor
on the day of admission instructing him to be evaluated for an
elevated serum calcium.

On admission, laboratory values of note were a serum calcium of
15.6 mg/dL and a creatinine of 3.2 mg.dL. The remainder of his
chemistry and hematologic values were within normal limits. An
initial troponin drawn in the emergency department was normal.

He described his primary complaint as if his surrounding were
moving. He did not complain of lightheadedness or syncope and
reported that his symptoms did not change with position. The
symptoms did not change if he closed his eyes or when he sneezed,
coughed, or strained. There was no associated nausea or vomiting.
His medical history was significant for severe GERD for which
he took ten to fifteen over-the-counter calcium carbonate tablets
daily with moderate symptom relief however had not had a
medical evaluation for these symptoms. He also reported severe
lower back pain that he attributed to his strenuous occupation
which began approximately nine months prior to admission. At
first, his back pain was alleviated by occasional ibuprofen use,
however at present, the patient was taking six to eight 200 mg
over-the-counter tablets of ibuprofen daily. He had not been
evaluated medically for his back pain. He also reported unilateral
glaucoma as a child and had required enucleation of his right eye.
Recently, he had arthroscopic exploration of his left knee and was
aware that he would eventually require knee replacement.
He reported that he knew of no allergies to medications and was
only taking the over-the-counter medications as above. His family
history was notable only for multiple members of his family with
coronary artery disease at a young age. He knew of no family
members with cancer or kidney disease. He occasionally drank
alcohol at social functions and had never been a tobacco user. He
works in maintenance and lives with his wife and daughter.
His review of systems was generally unremarkable. He reported
that he had decreasing urinary stream and volume and increasing
frequency during the past month. He reported no weight loss or
constitutional symptoms.
The temperature was 97.3ºF, the pulse was 73 and regular, the
blood pressure was 159/70 andd he was breathing comfortable at
16 respirations per minute. His oxygen saturation was 94% on
room air.
On physical examination, he was a pleasant and mildly obese man
in no distress. He was normocephalic, his left pupil reacted briskly
to light; he had a prosthetic in his right enucleated eye. There was
no notable nystagmus. The heart, lung, abdominal, and extremity
examinations were all unremarkable. His rectal examination

He was admitted with a diagnosis of hypercalcemia and for a
thorough evaluation of an underlying oncologic or endocrine
process. His initial treatment with 4 mg of zoledronic acid, 400
international units of salmon-calcitonin, as well as aggressive
intravenous hydration. He was placed on 40 mg intravenous
pantoprazole for relief of his reflux symptoms and he was provided
with acetaminophen for his back pain. On hospital day 2, the serum
calcium level was 8.3 mg/dL and his creatinine was 1.8 mg/dL.
A CT scan of his head was performed which was read to have no
intracranial pathology. His initial lumbar x-ray was read as
spondylothiasis, likely compression fractures at L4 and L5. A
follow-up MRI of lumbar spine showed multilevel disc bulging,
protrusions, and facet arthropathy with moderate bilateral
foraminal narrowing, however there was no evidence of
compression fracture as previously suggested.
A CT of the chest and abdomen were performed and showed no
acute pathology. The radiologist noted that severe gastroesophageal
reflux was evident by contrast refluxing into the esophagus as well
as faint nonobstructing calculi in the lower pole of the right kidney.
A renal ultrasound revealed no hydronephrosis or renal calcifications, and there was clear cortical medullary differentiation.
The results of his serum parathyroid hormone, vitamin D level,
and prostate specific antigen were all within normal limits. Urine
electrolytes were evaluated and the calculated fractional excretion
of sodium was 7.2%, suggestive of acute tubular necrosis. Of note,
his total cholesterol was 291 mg/dL and his low density
lipoprotein was 200 mg/dL.
The consulting urologist felt that his exam findings may be
consistent with asymmetric benign prostatic hypertrophy and
planned a transrectal biopsy as an outpatient. The consulting
gastroenterologist performed esophagogastroduodenoscopy and
the results were consistent with Barrett’s esophagus secondary to a
hiatal hernia. The patient was continued on pantoprazole.
Without evidence of an oncologic process or elevated parathyroid
hormone, the diagnosis of milk-alkali syndrome was made. High
dose ibuprofen likely resulted in acute tubular necrosis and a
decreased ability to excrete the high doses of calcium that the
patient was ingesting. The hypercalemia and acute renal failure
resolved and the patient was discharged on pantoprazole,
atorvastatin, and acetaminophen as needed for pain. He was
instructed to stop taking calcium carbonate and non-steroidal anti-
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inflammatory medications. Appointments with gastrointestinal,
urologic, and cardiovascular specialists as well as for a stress test
were made for the patient.

Discussion
There is an extensive list for the differential diagnosis of
hypercalcemia. Hyperparathyroidism is the most common cause
in ambulatory patients and malignancy is the most common cause
in hospitalized patients. The differential of hypercalcemia can be
divided into three major categories. Increased bone resorption can
be caused by hyperparathyroidism, cancer, hyperthyroidism, and
Paget’s disease. Increased calcium absorption can be caused by
increased calcium uptake and hypervitaminosis D. Miscellaneous
causes of hypercalcemia include drug toxicity and conditions such
as pheochromocytoma.
The presentation of this patient with milk-alkali syndrome and
underlying renal insufficiency has become rather rare since the
introduction of modern ulcer therapy. It has, however, increased
in frequency with more use of calcium carbonate for osteoporosis
prophylaxis. Subsequently, this syndrome has experienced an
increased prevalence in females, whereas before it was more
common in men . Prior to 1990, the milk-alkali syndrome
accounted for less that 2% of admissions related to hypercalcemia
with a small reported rise during the 1990s. Since calcium has
various roles in the body including cardiac and smooth muscle
contraction, and in platelet aggregation and function, proper
treatment and management of hypercalcemia is imperative.
In this patient, milk-alkali syndrome was suspected as the cause
of hypercalcemia after ruling out other causes of hypercalcemia.
In one case series, five patients who had milk-alkali syndrome
patients were ingesting large quantities of calcium and absorbable
alkali and presented with the triad of hypercalcemia, metabolic
acidosis, and renal failure. In two of these patients, renal failure
resulted in the need for dialysis. Kapnser, et al. reported on 297
heart and heart-lung transplant recipients who were being treated
with calcium carbonate after cardiac transplantation. This
treatment resulted in sixty-five patients who developed serious
hypercalcemia after transplantation. Thirty-one of these patients
experienced alkalosis and thirty-seven of had renal impairment.
The use of calcium in patients with preexisting renal insufficiency
is an important consideration. Four patients in a case report with
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mild, asymptomatic chronic renal failure took daily over-thecounter antacids and required hospital admission for
hypercalcemia. It is also imperative to monitor calcium use in
pregnant patients. Maternal prolonged hypercalcemia secondary
to primary hyperparathyroidism can affect the fetal circulation
and lead to suppression of fetal parathyroid function and lead to
neonatal hypocalcemia and tetany or may result in spontaneous
abortion and stillbirth. Therefore, monitoring calcium intake in
pregnant patients is also very important.
In the setting of hypercalcemia, initial medical management
includes intravenous fluids that promote the renal excretion of
calcium. In the setting of hypervitaminosis D such as those in
granulomatous disease, steroids are effective by inhibiting the
effects of vitamin D.2 In the setting of hypercalcemia of
malignancy, treatment of the underlying cancer promotes a return
to normal calcium levels. Bisphosphonates may also be used as
medical management and potentially may inhibit osteoclast
activity for up to one month. Calcitonin directly inhibits
osteoclastic bone resorption and promotes the renal excretion of
calcium by decreasing tubular reabsorption.
The milk-alkali syndrome is increasing in prevalence and should
be considered in any presentation of hypercalcemia. Patients
prophylactically taking calcium supplements or using over-thecounter antacids should be carefully monitored given their
increased risk for hypercalcemia.
■
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A 74 YEAR OLD WOMAN WITH LEFT SHOULDER PAIN
Jane V. Mayrin, MD
A 74 year old woman presented to the emergency department
complaining of two weeks of left shoulder pain. The pain was
sharp, 8 out of 10 in intensity, located in the left shoulder, made
worse with breathing, and associated with mild chest discomfort,
diaphoresis, and neck pain. There was no radiation and the pain
was not worsened with exertion. The patient has a history of
Warthin tumor of the left parotid gland and had undergone
laryngoscopy and polypectomy two weeks prior to presentation.
Around this time she developed the shoulder pain along with
overall weakness. At the time of presentation she reported the pain
was only present with deep breathing. She denied any shortness of
breath, headache, lightheadedness, dizziness, or cough.
In addition to the Warthin tumor, the patient has a history of
colon cancer with resection 25 years ago. She has a 50 pack-year
smoking history but denied alcohol or substance abuse. She was a
retired nurse and lived at home with her husband. Her family
history included a father who died in his eighties from a
myocardial infarction and a mother who died in her eighties from
cancer. She only took zolpidem 10mg at night as needed for sleep
and reported no allergies to medications.
On physical exam she was afebrile at 97.8 F, heart rate 87 beats
per minute, respiration rate 18 breaths per minute, blood pressure
117/79, and had an oxygen saturation of 98% on room air. Her
pupils were equal round and reactive to light with normal
extraocular movements. The left parotid gland was enlarged. The
neck was supple without lymphadenopathy and a jugular venous
distension of about 10 cm was noted. Her heart had a regular rate
and rhythm with a II/IV systolic murmur heard best at the left
sternal border with no radiation and no third heart sound.
Auscultation of the lungs revealed fine crackles at bilateral bases
without any wheezing. Her abdominal exam was unremarkable
and she had 2+ pulses in the lower extremities bilaterally without
any edema. The left upper extremity had full range of motion
without any pinpoint tenderness or effusion.
Laboratory data included hemoglobin of 11.4 g/dL, WBC count
of 8,300/mm3, platelets of 451,000/ mm3, BNP of 365 pg/mL
and a chemistry panel that was within normal limits. Her first set
of Troponin I was 0.23 ng/mL, with the trend of 0.22, 0.20, 0.15
(Reference range <0.05 to 0.5 ). The EKG showed normal sinus
rhythm at 85 bmp, with Q waves in leads II, III, and inverted Twave in lead III. Chest x-ray showed bibasilar atelectasis with
prominent right paratracheal stripe likely due to vascular
congestion without any interstitial edema. Due to the nature of
the patient’s pain, she had a chest CT performed while in the
Emergency Department which showed no pulmonary embolus
but was notable for a 3 cm left ventricular aneurysm of the
posterolateral wall at the base of the heart along with a small
amount of adjacent pericardial fluid and thickening (Figure 1).

Figure 1. CT chest showing 3cm left ventricular aneurysm
of the posterolateral wall at the base of the heart.
The patient was admitted to the medicine service for further work
up of her pain and to rule out myocardial infarction. Even though
her cardiac enzymes were not in a negative range, she ruled out
for myocardial infarction with three sets of enzymes within the
normal reference range. The night following admission the patient
developed rapid atrial fibrillation. Given her baseline hypotension,
her rate was controlled with amiodarone, and she was fully anticoagulated with enoxaparin.
The following morning a persantine stress test demonstrated a
large inferolateral perfusion defect with partial reversibility at the
basal segments indicative of persantine-induced ischemia. The
left ventricular ejection fraction was measured as 56%. She also
had a transthoracic echocardiogram performed, which was
notable for a region of the mid posterior wall with very marked
thinning and aneurysmal dilatation. Her left ventricle internal
dimensions and wall thickness was normal with overall moderate
LV systolic dysfunction with inferior, posterior, and basal-mid
lateral akinesis, mild mitral and tricuspid regurgitation and
borderline pulmonary hypertension.
Given the findings of the above diagnostic studies, the patient
was scheduled to have coronary catheterization the following
morning. However, that night the patient was found unresponsive
and asystole noted on the cardiac monitor. Despite resuscitative
efforts during the PEA code, she never regained a pulse or a blood
pressure and died that evening.
Autopsy revealed 500 cc of hemopericardium (Figure 2a and 2b),
atherosclerotic cardiovascular disease with thrombotic occlusion
of circumflex artery, 50% occlusion of LAD and RCA, and
posterior wall recent myocardial infarction with aneurysmal
dilatation.
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• Rupture of the LV free wall;

ventricle compared to the right ventricle and rarely involves the
atria. The infarct commonly affects the anterior and lateral walls
of the left ventricle and the rupture typically occurs near the
junction of the infarcted and normal myocardium

• Rupture of the interventricular septum;

Morphologic types of free wall rupture

• Development of mitral regurgitation.

1 - normal wall thickness with through and through rupture

This discussion will focus mostly on the rupture of LV free wall.

2 - expansion of soft necrotic zone with wall rupture

Incidence

3 - numerous small perforations in the area of myomalacia
(multicanalicular rupture)

Discussion
There are 3 major mechanical complications of acute myocardial
infarction:

Myocardial free wall rupture is the third most common cause of
death after myocardial infarction and is 10 times more common
than rupture of ventricular septum or papillary muscles. It is a
relatively common finding in patients who died of acute
myocardial infarction, with some large studies showing cardiac
rupture in 14-26% of these patients. However, of all patients with
acute myocardial infarction, the incidence of cardiac rupture is
only 1-3%. If thrombolytics are used, death from rupture occurs
earlier among these patients and often within 24 hours of drug
administration. However, the use of thrombolytics does not
increase the incidence of myocardial rupture.
Risk factors for myocardial rupture include the use of
thrombolytics, lack of prior history of angina or myocardial
infarction, ST-segment elevation or Q wave development on the
initial ECG, peak CK-MB above 150 IU/L, anterior location of
the infarction, age greater than 70, and female sex. These
associations suggest that the absence of collateral blood flow, as
suggested by the lack of previous ischemic symptoms, and the size
of the infarct are important determinants of the likelihood of
myocardial rupture.

Pathology
Myocardial rupture occurs within the first 5 days after acute
myocardial infarction in about 50% of cases and within 2 weeks
in more than 90% of cases. It more frequently involves the left
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4 - normal wall thickness with rupture of the outer layer of
infarcted area
5 - large epicardial hematoma under pressure
6 - hemorrhagic infarction with grossly intact but abraded and
leaking epicardial surface (bleeding infarct)

Evolution of rupture
Within the first week after the myocardial infarction, neutrophils
populate the infarcted area between the necrotic myocytes and
produce a zone of coagulative necrosis which is very soft and
predisposed to rupture. A myocardial rupture usually occurs at
the interface between necrotic and spared myocardium. Once
rupture occurs, the pericardium rapidly fills with blood
(hemopericardium) and as a result the right ventricle cannot fill
and cardiac output rapidly declines.

Pathology of healing
As mentioned above, the initial phase of acute myocardial
infarction is characterized by neutrophil infiltration and myocyte
necrosis. The healing phase (after the first week), however, is
typified by mononuclear cell and fibroblast infiltration and the
absence of polymorphonuclear cells. Resorption of necrotic
myocytes often precedes scar formation with accumulation of
fibrillar collagen into an increasingly organized network. The
complete healing process takes 5- 6 weeks and results in a stable
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Figure 2a. Posterior wall ventricular aneurysm

Figure 2b. Hemopericardium on autopsy.

scar absent of cellular infiltration. The thinned infarct region is
stable and not very vulnerable to mechanical disruption.

frank rupture with tamponade and death, formation of a false
aneurysm walled off by pericardial tissue and communicating with
the left ventricle through the perforation, or formation of left
ventricular diverticulum. Incomplete rupture may present as
recurrent chest pain, nausea, restlessness, abrupt and transient
hypotension. It can also cause ECG features mimicking regional
pericarditis.

New insights into pathology of free wall rupture
There is a suggestion that defective cardiac remodeling may
predispose the heart for rupture. The matrix metalloproteinase
(MMP) has been shown to play an important role in cardiac
extracellular matrix (ECM) remodeling and cardiac rupture.
Over-expression and activities of MMPs induced by TNF (from
inflammatory response) at the site of myocardial infarction may
increase the degradation of existing collagen in the early stage of
infarction, thus contributing to cardiac rupture.

Effects of reperfusion
It has been shown that rupture is less common in patients with a
patent infarct- related coronary artery. Rupture typically occurs in
an area that has been infarcted without successful reperfusion. A
number of studies has shown that thrombolytic therapy early after
myocardial infarction improves survival and decreases risk of
myocardial rupture. Late administration of thrombolytics (6-24hr
after onset of symptoms) does not increase the risk of cardiac
rupture, but appears to accelerate the time of onset of rupture
events (within 24 hrs of treatment).

Clinical presentation
Myocardial rupture may present as sudden death in an undetected
or silent myocardial infarction. Complete rupture of LV free wall
leads to hemopericardium, cardiac tamponade, and subsequent
death. Presence of rupture is first suggested by sudden acute right
heart failure and shock, which then progresses rapidly to PulselessElectrical-Activity (PEA) codes. During the resuscitative efforts,
emergent pericardiocentesis will confirm the diagnosis and
transiently relieve the tamponade.
Incomplete rupture occurs when organized thrombus and the
pericardium seal the ventricular perforation. This may progress to

Management
The survival of patients with free wall myocardial rupture largely
depends on rapid recognition and administration of immediate
therapy. Bedside echocardiogram and echocardiogram-guided
pericardiocentesis should be obtained if the diagnosis of rupture
is suspected. If the pericardial fluid includes blood, the patient
should immediately proceed to surgery. Fluids, inotropic agents,
pressors, and intra-aortic balloon pumps can be used for
hemodynamic stabilization while the patient is being transported
to the operating room.
■
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RUPTURE RECURRENCE AFTER SURGICAL REPAIR OF A POSTINFARCTION
VENTRICULAR SEPTAL RUPTURE IN THE REPERFUSION ERA
Apurva D. Shah, MD1 and Alan K. Tannenbaum, MD2
A 63-year-old male is admitted to the CCU for chest pain,
shortness of breath, and an elevated troponin.
The patient is a 63-year-old male with a past medical history
significant for hypertension and hypercholesterolemia who
presented to the emergency room with a chief complaint of
shortness of breath and chest pain. The chest pain began two days
prior and was associated with nausea. The patient proceeded to
have increasing shortness of breath over the subsequent two days
which brought him to the emergency room for evaluation.
In the emergency room, the patient was noted to be in atrial
fibrillation with rapid ventricular response and hypotension. He
was cardioverted into sinus rhythm. The ECG showed sinus
rhythm, RBBB and inferior myocardial infarction age
indeterminate. The cardiac enzymes drawn in the emergency
room showed a troponin of 30 ng/mL. The patient was transferred
to the Coronary Care Unit. An echocardiogram performed in the
Coronary Care Unit demonstrated a ventriculoseptal defect. The
patient was emergently taken to the catheterization lab.
The right heart catheterization demonstrated a mean right atrial
pressure of 18 mmHg, right ventricular pressure of 42/18 mmHg,
pulmonary pressure of 40/24 mmHg, and a pulmonary capillary
wedge pressure of 23 mmHg. The right atrial oxygen saturation
was 31% and the right ventricular oxygen saturation was 81%.

The left ventriculogram demonstrated severe anterolateral
hypokinesis and apical hypokinesis. There was evidence of dye
exstravasation just superior to the anterolateral segment with late
filling of the pulmonary artery suggesting a left to right shunt.
Coronary arteriography demonstrated a 100% proximal occlusion
of the left anterior descending artery after the first diagonal. The
left circumflex artery had diffuse disease in the marginal system.
The remaining vessels were angiographically normal.
The patient was taken emergently to the operating room.
Intraoperative transesophageal echocardiogram revealed a large
ventricular septal defect in the apical portion of the septum
located primarily anteriorly. The patient underwent coronary
artery bypass grafting of the left internal mammary to the left
anterior descending artery and the left radial artery to the first
diagonal artery. The patient also received a bovine pericardial
patch repair of the anterior apical VSD.
The remainder of his hospital stay was unremarkable and he was
discharged, however soon after discharge the patient began to
develop progressively worsening shortness of breath requiring
readmission to the hospital.
Echocardiogram showed a large color flow turbulence moving
across the septum consistent with a VSD. This was confirmed by
cardiac MRI which showed a VSD between the left ventricle and

1 Apurva Shah, MD was a resident of
Thomas Jefferson University Hospital and
presently is a cardiology fellow at
UMDNJ/Robert Wood Johnson Medical
School in the Department of Medicine,
Division of Cardiovascular Diseases
2 Alan Tannenbaum, MD is an assistant
professor of medicine at UMDNJ/Robert
Wood Johnson Medical School in the
Department of Medicine, Division of
Cardiovascular Diseases

Figure 1. 100% occlusion of the mid
Left Anterior Descending Artery
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Figure 2. Irregularities of the Right
Coronary Artery
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right ventricular outflow tract with a Qp:Qs ratio of 1:2.5. This
appeared secondary to a torn patch.
The patient underwent a repeat cardiac catheterization. The left
anterior descending artery was 100% occluded (Figure 1). The
Right coronary artery demonstrated eccentric lesions (Figure 2).
The LIMA to LAD graft was patent (Figure 3). The Radial graft
was 100% occluded proximally (Figure 4). The left ventriculogram demonstrated dye extravasation into the right ventricle
consistent with a VSD (Figure 5 ) and akinesis of the anterolateral
and septal segments.
The patient was taken to the operating room where inspection of
the ventricular cavity revealed a 2 cm diameter hole in the anterior
left ventricle extending into the right ventricular outflow tract.
This area was closed using the patient’s own ventricular muscle
with a sandwich technique employing felt.
The patient tolerated the operation and was discharged from the
hospital after 2 weeks. Currently, the patient is doing well with
no complaints of chest discomfort, shortness of breath, orthopnea.

Discussion
Ventricular septal rupture (VSR) is a potentially fatal mechanical
complication of an acute myocardial infarction. Prior to the use
of reperfusion therapy, ventricular septal ruptures complicated
three percent of acute myocardial infarctions.1 With reperfusion
therapy, this has decreased to 0.2%.2 Early surgical treatment

Figure 3. LIMA graft to Left Anterior
Descending Artery

remains the treatment of choice. The operation on weak and
fragile myocardium may lead to postoperative recurrence of the
ventricular septal rupture. We present the case of a 63-year-old
male who developed a ventricular septal rupture after an acute
anterior myocardial infarction treated with percutaneous coronary
intervention. This VSR required surgical repair. His course was
complicated by a recurrence of the VSR and redo-surgery.
Ventricular rupture complicating acute myocardial infarction
leads to a high mortality. Reperfusion therapy demarcates a change
in the incidence and demographics of septal rupture complicating
acute myocardial infarctions. These differences have been
demonstrated by the Global Utilization of Streptokinase and
Tissue Plasminogen Activator for Occluded Coronary Arteries
(GUSTO-I) trial.
Ventricular septal rupture is the result of a full thickness infarction
of the interventricular septum. This is followed by necrosis that
results in septal rupture. This necrosis can produce two types of
pathologic ruptures, either a simple or complex rupture. The
simple rupture represents a direct connection between the two
ventricles. A complex rupture has a convoluted communication
between the two ventricles. Complex morphology is more often
associated with inferior wall myocardial infarctions, whereas
simple morphology is seen after anterior wall myocardial
infarctions.4

Figure 4. 100% occluded Radial graft
proximally

Figure 5. Left Ventriculogram
demonstrating dye extravasation into
the right ventricle
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Right heart catheterization is the standard for diagnosing
ventricular septal rupture. Sampling of the oxygen saturations
demonstrate a step up between the right atrium and pulmonary
artery. Transthoracic echocardiogram with color flow doppler can
also be used to diagnose. Left ventriculography has also been used
in diagnosing; however, the contrast load may be detrimental to
the ventricular and renal function.
There exists a significant difference in outcomes and patient
demographics in relation to the development of ventricular septal
ruptures when comparing the pre and post-thrombolytic era. The
GUSTO-I trial established the incidence of VSD after acute MI
in patients treated with thrombolytic therapy and to identify the
enrollment characteristics and angiographic patterns associated
with its occurrence2. Patients enrolled in the GUSTO-I trial
presented to and emergency room within six hours of an STsegment elevation myocardial infarction. Patients were
randomized to streptokinase with either subcutaneous or
intravenous heparin, accelerated alteplase with intravenous
heparin or the combination of alteplase and streptokinase with
intravenous heparin. Patients who developed VSDs were
identified by review of case reports.
Review of the GUSTO-I data demonstrated an incidence of 0.2%
of patients who developed VSDs after acute myocardial
infarctions. The median time from MI symptom onset was 1 day.
This differs from the 3-5% and 3-5 days without thrombolysis.
Risk factors for the development of VSDs in the post-throbolytic
era included: elderly, female and hypertensive, no history of
smoking, anterior infarction, tachycardia and worse Killip classification on admission.
Patients who developed VSDs were found to have TIMI grade 0
or 1 flow, and 57% had total occlusion of the infarct artery. The
left anterior descending artery was more often the infarct related
artery. This is consistent with findings in patients not receiving
reperfusion5.
Despite the institution of thrombolytic therapy, the mortality
from VSD remains high. From the GUSTO-I data there is no
difference in mortality at 30 days as compared with 1 year. It can
be surmised that if a patients survives the initial insult his
prognosis is good.
Surgical treatment remains the standard of care for patients with
VSDs. The mortality from medical management is 94%. Early
surgical repair is technically demanding. Early surgery is associated
with a 40% incidence of residual shunt6. Two additional
difficulties in the operation are identifying the margins of the
infarct and suturing the patch. A pericardium sutured to the
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myocardium is used to decrease the amount of residual shunt.
The pericardium also reduces the amount of stress on the sutures
due to its compliance.
Despite the improved surgical methods, rupture reoccurrence
remains a feared complication. Review of the literature
demonstrates a reoccurrence of the VSR between 5 and 25% of
operated patients7,8. Early thrombolysis is the main determinant of
recurrence of the VSR. There is a higher incidence of VSR after
thrombolysis9. There are two possible reasons for this. The first may
be that there is a viable appearance to the infarcted tissue after
thrombolysis. This may cause an underestimation of the infracted
area and lead to a mismatch in reconstruction of the repair. The
second may be the edema that is caused to the myocardium by
reperfusion injury. Once the edema resolves there may be added
stress on the sutures leading to rupture of the sutures.
Reperfusion therapy, in particular thrombolysis, has had an impact
on the mechanical complication of acute myocardial infarction
known as ventricular septal rupture. Thrombolysis has influenced
the incidence, timing and patient demographics. Although the
incidence has decreased the onset from symptoms of myocardial
infarction is now 24 hours. The elderly, female and hypertensive
are predisposed to this complication. Once treated surgically, there
is a higher incidence of recurrence in those patients treated with
thrombolytics. The effect of percutaneous coronary intervention
on the outcome of ventricular septal rupture remains to be seen. ■
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A 53-YEAR-OLD WOMAN WITH WORSENING RASH AND DIARRHEA
Bryan Kavanaugh, MD
A 53-year-old white female was admitted to the Bone Marrow
Transplant Unit with a worsening pruritic rash.
The patient had a history of IgG lambda multiple myeloma status post
autologous stem cell transplant one year prior and more recently, matched
sibling allogenic transplant. Since transplantation, she had a history of
rash, which was diagnosed as graft-versus-host disease (GVHD) by skin
biopsy. During that same hospitalization, she had a transjugular liver
biopsy to rule out GVHD which was complicated by a large intrahepatic
and subcapsular hematoma. A catheter to drain the hematoma was placed
by interventional radiology, which was still in place. The patient was
discharged following her allogenic transplant with successful engraftment
of donor stem cells on bone marrow biopsy, without evidence of residual
multiple myeloma. She was on GVHD therapy with tacrolimus,
prednisone, and Cellcept. Recently, her rash had returned and was
becoming increasingly pruritic over several weeks prior to admission.
The patient did not report headache, sore throat, chest or abdominal
pain, dyspnea, diarrhea, or dysuria. She had no other significant past
medical or surgical history. She reported occasional alcohol
consumption and a remote, but limited smoking history. Her activities
had been limited recently by her illness and she denied any travel. She
had no knowledge of starting any new medication, lotions, detergents,
or soaps in the recent past.
On this admission, the vital signs were normal and she appeared
chronically ill. The head, neck, lungs, and heart were unremarkable.
Her abdominal exam was significant for a mildly tender right upper
quadrant without rebound or guarding. She had normoactive bowel
sounds. She had a right upper quadrant drainage catheter with serosanguinous drainage. Her dermatologic exam was notable for a
maculopapular rash on her back, abdomen and thighs noted, which
was non-blanching. There were no vesicles or bullae.
Upon admission, skin biopsy revealed interface dermatitis consistent
with GVHD and the patient was placed on intravenous steroids. In
addition, patient had an Adenovirus PCR of 4,600 copies. On hospital
day 7, the patient developed acute diarrhea. Stool sample was positive
for white blood cells; stool culture and C. difficile were negative.
Adenovirus was isolated from the stool. Due to concern for GVHD of
the colon, patient had a colonoscopy performed, revealing multiple
ulcerations, colitis in the sigmoid colon, and diverticulosis (Figures 1
and 2). Biopsies were obtained from the ulcer and the sigmoid colon.
Culture of the ulcer was positive for adenovirus and negative for CMV,
HSV, and Enterovirus. Pathology of ulcer biopsy revealed glandular
epithelial cells with acute inflammation and intranuclear inclusions,
morphologically consistent with adenovirus. Immunohistochemical
staining of the colon biopsy was negative for HSV and CMV and was
eventually was positive for adenovirus.
Initially on steroids, her GVHD dermatitis resolved and she was treated
with Cidofovir and IVIG for her adenovirus infection. Her diarrhea
and adenovirus PCR titer both responded appropriately to treatment.

Discussion
Adenovirus is a common infectant causing mild and self-limited
infections in immunocompetent individuals. In an immunocompromised population, such as bone marrow transplant recipients, it can
have severe consequences. Patients who have undergone allogenic stem
cell transplant are at highest risk for adenovirus disease. Other risk

Figure 1. Area of ulceration
in sigmoid colon.

Figure 2. Punctate erythema of
sigmoid colon.

factors are age (children more often than adults), T-cell depleted grafts,
presence of GVHD, and the use of mismatched and unrelated donors.
It can manifest as pneumonia, hepatitis, hemorrhagic cystitis, interstitial
nephritis, gastroenteritis/colitis, and encephalitis. In one-half of the
patients with invasive adenoviral disease, the outcome is death.
Adenovirus can be acquired via a primary infection (person to person),
or via reactivation of latent infection/donor organ infection. Adenovirus
colitis is not well studied, as most studies rely on detection of virus in
stool in symptomatic patients without tissue confirmation. Often
adenoviral infections of the bowel coexist with GVHD.
Adenovirus can be diagnosed by a number of means. Viral culture it the
most sensitive and specific. Cultures from stool or urine may be positive
for months after an acute infection in an immunocompromised patient.
Viral antigens detected by enzyme-linked immunosorbent assay (ELISA)
are not as sensitive as culture, but can give rapid diagnosis. PCR can be
used to detect adenovirus in body fluids and tissues and is highly sensitive
and specific. Histopathology can also be used to identify the characteristic
intranuclear inclusions seen in adenovirus infection. These can be similar
to CMV; however, adenovirus does not cause intracytoplasmic inclusions
or multinucleated cells like CMV. Immunohistochemical stains can be
used to identify to identify HSV, CMV, or adenovirus. Electron
microscopy can identify the characteristic icosahedral virus seen in
adenoviral infections present in the nuclei of infected cells.
Since this infection is associated with significant mortality in the posttransplant population, it is often treated. Antiviral agents are the mainstay
of treatment, although limited evidence is available for efficacy.
ganciclovir, ribavirin, and vidarabine have shown some activity in vitro,
and there are a number of case reports associating Ribavirin with a
successful outcome. Cidofovir, a nucleotide analog effective against a
number of viruses, has been shown to be active against adenovirus. No
prospective, controlled studies have been performed to date. Intravenous
Immunoglobulin (IVIG) theoretically contains neutralizing antibodies
against adenovirus; it has been used in conjunction with antiviral therapy
in a number of reports. Another strategy used is reduction in immune
■
suppression as this allows clearance of virus in some patients.
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SARCOID CARDIOMYOPATHY
Sivakumar Srinivasan, MD and Emanuel Chryssos, MD
The patient is a 40 year old African-American female with no
significant past medical history who presented to the ED with a 2
week history of lower extremity edema and shortness of breath.
She also noticed intermittent palpitations, dry cough, easy fatigue
and a 30 pound weight loss. On examination, the patient’s
temperature was 98.9F orally, pulse was 155-170 beats per
minute, and blood pressure was 133/93 mmHg. EKG revealed
long P-R tachycardia with heart rate of 170. Chest X- ray was
done and showed large right pleural effusion with compressive
atelectasis and small left pleural effusion. Transthoracic echocardiogram at the time of admission was consistent with severe global
LV dysfunction with EF-20% and moderate pulmonary
hypertension. CT Chest, which showed bilateral hilar adenopathy
and subsequent biopsy was consistent with non-caseating
granulomatous lesion. Her initial basic laboratory values,
including TSH level, were normal except for BNP which was 569.
She underwent left and right heart catheterization, which revealed
normal coronary arteries and decreased cardiac index. During the
hospital stay, telemetry monitors revealed rhythms consistent with
various degrees of AV conduction abnormalities. She was started
on steroids and intravenous milrinone for possible sarcoid
cardiomyopathy and listed for heart transplant. Her symptoms
were gradually improved and she was discharged home with
steroids, beta blockers, diuretics, ace inhibitors and an implantable
defibrillator. She is currently followed as an outpatient and doing
extremely well without any cardiac symptoms.

Myocardial sarcoidosis may have restrictive as well as congestive
features because cardiac infiltration by sarcoid granulomas results
not only in increased stiffness of the ventricular wall but also in
diminished systolic contractile function. Occasionally patients
with extensive involvement of the left ventricular myocardium
develop left ventricular aneurysms; it has been suggested that
corticosteroid treatment may convert granulomas to scar tissue
and contribute to the development of aneurysmal dilatation. Firstdegree heart block due to disease of AV Node or bundle of His,
and various types of intraventricular conduction defects, are
common among patients with cardiac sarcoidosis. Complete heart
block is the most common finding in patients with clinically
evident cardiac sarcoidosis, and occurs at a younger age in patients
with sarcoidosis than in individuals with complete heart block
due to other etiologies. Corticosteriods can be used to halt
progression of disease, but it has little to no benefit once EF is
<30%. Heart transplantation for sarcoidosis with advanced heart
failure has been performed less commonly than lung transplantation. Survival has been similar to that of patients undergoing
heart transplantion for other indications. Despite the possibility
of recurrence of sarcoidosis in the graft or the appearance of
progressive extracardiac disease, available evidence supports
transplantation for cardiac sarcoidosis in patients with extensive
cardiac involvement and advanced heart failure as long as there is
minimal extracardiac involvement.
■
Credits: H&E stains prepared by Bernadette Wildermore MD

Figure 1. Hematoxylin and
Eosin stain of lymph node at
low power magnification
showing multiple noncaseating granulomas.
(arrows)

23

Case Reports

Figure 2. Higher power
magnification reveals lack of
necrotic material within the
granuloma. Also seen is peri granulomatous connective tissue
(arrow) consistent with fibrosis
which can sometimes be a marker
of long-standing sarcoid.
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IMAGE IN MEDICINE
Amy Baranoski, MD
Pictured here is the back of a man with leprosy who had been
treated at Acworth Leprosy Hospital in Mumbai, India. Note the
diffuse, macular, hypopigmented rash. Leprosy is a chronic disease
caused by infection with Mycobacterium leprae. The disease can
affect a variety of organs including peripheral nerves, skin, muscle,
eye, bone, and testes. Leprosy is diagnosed clinically by the
presence of at least one of the following: hypopigmented patches,
loss of cutaneous sensation, thickened nerves, and acid-fast bacilli
in nasal or skin smears.
The prevalence of leprosy has decreased worldwide due to multidrug therapy and public health programs focused on education
and detection of the illness. Multi-drug therapy consists of the
bactericidal drugs: rifampin, dapsone, clofazimine, ethionamide
and protionamide. Quinolones, minocycline, and clarithromycin
are not part of the normal regimen, but can be combined with
rifampin, primarily in single lesion leprosy.
■

In November 2005 Dr. Baranoski
spent several weeks observing
various clinics and hospitals in
Mumbai, India where she
captured the following image.
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VARICELLA PNEUMONIA
Sivakumar Srinivasan, MD, Rangadham Nagarakanti, MD and Sandhya Nalmas, MD
44 year old Hispanic male with no significant past medical history,
recently discharged from prison, presented to the hospital with rash
all over the body with itching. The rash started on the face, at the
back of the ear and then spread to the trunk and legs. He denied
fever, chills, cough, shortness of breath or sick contacts. Physical
examination revealed a young, comfortable looking male with stable
vital signs except for a temperature of 102 F. Skin examination was
significant for maculo-papular rash (Figures 1 and 2) with vesicles
and pustules, some of which were crusted, found diffusely over face,
chest, abdomen, and extremities yet sparing the palms and soles.
Oral cavity also showed mucosal lesions. The laboratory values
included WBC count of 7,700/mm3 with 78% segmented
neutrophils, Hgb of 15.4 g/dL, ESR of 13, creatinine of 0.8 mg/dL,
albumin of 3.3 g/dL, aspartate transaminase of 73 IU/L, alanine
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transaminase of 70 IU/L, and lactate dehydrogenase of 924 IU/L.
Arterial blood gas on room air showed a PaO2 of 70. Chest x-ray
(Figure 3) showed diffuse bilateral alveolar infiltrates. Chest CT
(Figure 4) was significant for wide spread interstitial pneumonia.
Serology was positive for varicella zoster IgM antibodies. The
patient was treated with intravenous acyclovir 800 mg every 8 hours
for 7 days with excellent clinical improvement and without any
adverse sequelae.
■
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Figure 1. Maculopapular rash with vesicles and pustules on torso.

Figure 2. Maculopapular rash on extremities.

Figure 3. Chest X-ray showing Diffuse Bilateral alveolar infiltrates.

Figure 4. Chest CT showing interstitial pneumonia.
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RECURRENT SPONTANEOUS CORONARY ARTERY DISSECTIONS
Sivakumar Srinivasan, MD and Rangadham Nagarakanti, MD
A 41-year-old Caucasian female with a history of hypertension
presented with exertional chest pain. Her vital signs were stable
on admission and physical examination was unremarkable. An
Electrocardiogram (EKG) revealed inferior ST segment elevations
consistent with acute myocardial infarction and cardiac enzymes
were elevated. She was started on heparin, and underwent
immediate cardiac catheterization. Cardiac catheterization
revealed an occluded distal right posterior descending artery
(RPDA), suggestive of intracoronary thrombus (Figure 1).
However close inspection of the RPDA revealed subtle evidence
of a dissection. Ventriculography showed preserved left ventricular
function and mild hypokinesis of the distal inferior segment. The
RPDA was non- intervenable and she was medically managed.

Figure 1. Dissection in the right posterior
descending artery (RPDA).

The hypercoagulable work up was negative. The patient remained
stable for the next two days and was discharged home. Six days
later, she returned to the emergency room with recurrent chest
pain and at that time the EKG showed ST segment elevations in
both the inferior and lateral leads. She was started on intravenous
nitroglycerin and heparin and was taken to the cardiac catheterization lab. Angiography showed spontaneous dissection in the left
circumflex artery (Figure 2) and another dissection in the
posterior descending branch of right coronary artery (Figure 3).
Both the circumflex and RPDA vessels were deemed too small for
percutaneous intervention. There was no recent history of trauma,
cocaine use, estrogen use or pregnancy. The patient was discharged
home with medical management.
■

Figure 2. Spontaneous dissection of the
left circumflex coronary.

Figure 3. Spontaneous dissection of the
posterior descending branch of right
coronary artery.
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WELLENS SYNDROME
Nicole Farmer, MD and Michael Cohen, MD
A 76 year-old African-American female with a history of
hypertension, type II Diabetes Mellitus, hyperlipidemia, and
gatroesphageal reflux presented to emergency room complaining
of epigastric pain radiating to left substernum which started the
night before presentation. The onset of her sharp pain was at rest,
lasted for two hours, and was aggravated by eating and drinking.
Her chest pain was followed by gagging and regurgitating of liquid
contents. Her chest pain was non-exertional, and not associated
with shortness of breath, diaphoresis, nausea, or vomiting. In the
Emergency Department, her pain subsided with two sublingual
nitroglycerins and 2 milligrams of intravenous morphine. On
further questioning the patient stated that the pain had been
intermittent for two months. She had seen her outpatient doctor
one week prior to admission, who recommended rantidine and
an outpatient stress test.
Past cardiac history was significant for a Persantine stress test two
years prior that showed normal myocardial perfusion. An echocardiogram done 3 months prior showed asymmetric septal
hypertrophy, impaired relaxation of left ventricle, and a low-normal
left ventricular systolic function with ejection fraction of 55-60%.
Physical exam on admission revealed an afebrile, elderly woman
with stable vital signs who showed no signs of discomfort. She
had normal heart sounds with no murmurs and no reproducible
chest pain. Her lung, abdomen and extremity examinations were
likewise unremarkable. At the time of admission, her blood work
was remarkable for hemoglobin of 12 g/dL, creatinine of 1.3
mg/dL, amylase of 97 U/L, lipase of 20 U/L, myoglobin of 143
ng/mL, and troponin I of 0.50 ng/mL (reference range 0.05 0.50). A chest x-ray performed in Emergency Department showed
no acute disease. The admission EKG is shown below (Figure 1).

Figure 1 shows the EKG on initial presentation when the patient
was pain-free. There were new changes when compared to prior
EKG. The major finding was biphasic T waves in V2-V3 with
convex morphology of QRS complex. Troponin drawn on arrival
was 0.50 (reference range <0.05 to 0.50). Eight hours after initial
presentation, her second troponin returned at 4.09. A subsequent
ECG (Figure 2) done, again the patient was pain-free, revealed
symmetrical inversion of T waves in V2 and V3.
The patient was taken to cardiac catheterization on the next day
and was found to have a 99% occlusion of left main stem, 99%
occlusion of LAD with active thrombus, and 50% occlusion of
RCA. Patient was emergently taken for CABG, where she
underwent grafting of the LAD, obtuse marginal, and PDA.

Discussion
In retrospect, the patient’s history was consistent with unstable
angina, although she did manifest atypical symptomatology.
Because of her past medical history including GERD and diabetic
neuropathy, such comorbidities may have masked true cardiac
chest pain. Unfortunately, our patient went on to develop anterior
myocardial infarction.
The clinical history and EKG findings are consistent with Wellens
syndrome (WS). The syndrome is also referred to as LAD
coronary T-wave syndrome. Syndrome criteria include T-wave
changes plus a history of anginal chest pain without serum marker
abnormalities: no pathological Q waves, no ST segment elevation,
and no loss of precordial (V1-V6) R waves. EKG abnormalities of
WS appear in one of two ways. The more common variant
presents with symmetric and deeply inverted T waves in the
precordial leads, usually V2 and V3 (Figure 2). The less common
variant presents with biphasic T waves in the precordial leads,
again, usually in V2 and V3 (Figure 1). This case highlights the

Figure 1. Biphasic T waves in V2 and V3 could easily be mistaken for u waves.
This represents an uncommon variant of Wellens Syndrome.
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Figure 2. Symmetric inversion of T waves in V2 and V3 is the common variant of Wellens Syndrome.
fact that EKG abnormalities are present in patients even when
they do not have the typical chest pain. Moreover, the EKG
findings tend to disappear during bouts of angina with
normalization of ST segment or T wave abnormalities.
WS was originally described in 1982 by Wellens in his paper with
de Zwann and Bar. In this landmark study, 75% of all patients
with WS EKG pattern went on to develop extensive anterior
myocardial infarctions within a few days of hospitalization despite
management of pain with medical management. In a follow up
retrospective study where urgent PCI was performed on all 180
patients meeting WS criteria, 100% were found to have at least a
50% obstruction in their LAD artery
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It is essential that clinicians recognize that patients admitted to
the hospital because of unstable angina who show the characteristic EKG findings described have a high likelihood of having a
critical proximal LAD lesion. Such patients are at high risk for
the development of an extensive anterior wall MI as was the case
for the patient described. In this subgroup of patients, urgent
coronary angiography and, when possible, coronary revascularization should be undertaken. Furthermore, exercise stress tests
are contraindicated due to presence of extensive lesions and several
case reports of death following treadmill stress testing.
■
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A 19 YEAR OLD GIRL WITH LIGHTHEADEDNESS AND PALPITATIONS
Andrew Rose, MD
A 19 year old patient with a past medical history significant only for
recurrent syncope presented to the emergency department after 90
minutes of palpitations, chest tightness, lightheadedness and shortness
of breath. Electrocardiogram on admission is shown in Figure 1.

electrocardiogram is shown in Figure 3. Interestingly, the delta
waves on her initial electrocardiogram (Figure 2) are no longer
present, an indication of the success of the procedure. She
tolerated the procedure well and was discharged the following day.

The patient was immediately treated with infusions of
procainamide and amiodarone and the tachycardia broke to reveal
a sinus rhythm. An electrocardiogram from several hours later is
shown in Figure 2.

In 1930, Louis Wolff, Sir John Parkinson, and Paul Dudley White
published a review of 11 patients who suffered from bouts of
tachycardia similar to this patient. To this day, their names are
still well associated with the condition.
■

The patient underwent electrophysiologic study and a trans-septal
ablation of a left lateral accessory pathway. The post-procedure

References
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Figure 1. Wide complex tachycardia with a ventricular rate of approximately 250.
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Figure 2. The rhythm is regular and initiated by the sinus node. There are slightly shortened
PR intervals and the QRS has a slurred upstroke in leads V3-V5 (arrows).

Figure 3. Post ablation EKG. Note the disappearance of the delta waves present in Figure 2.
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RISK OF ISCHEMIC STROKE ASSOCIATED
WITH LOW-DOSE ORAL CONTRACEPTIVE USE: A META-ANALYSIS
Dae Hyun Kim, MD, MPH1, Joachim Bleys, MD, MPH2, Marlis Gonzalez-Fernandez, MD3,
Rebecca Gottesman, MD4 and Michelle Hudspeth, MD5
Abstract

Background

Context: Oral contraceptive (OC) use has been shown to be
associated with increased risk of ischemic stroke. However, most
studies were conducted before low-dose OC became available.

Since the introduction of oral contraceptive (OC) in the late
1950s, a number of epidemiologic studies have shown that OC
use is associated with increased risk of ischemic stroke.1,2 However,
most of the studies conducted before 1980s were based on OCs
containing high-dose estrogen (80 or 100 _g) that are no longer
used. Oral contraceptives containing low-dose estrogen (less than
50 _g) became available in the early 1970s. The formulation
currently in widespread use in the Unites States contains 30 or 35
_g of estrogen.3 Thus, it is not reasonable to generalize about the
risk of ischemic stroke associated to the use of low-dose OC from
the findings based on high-dose formulations.

Objective: To determine whether low-dose OC use is associated
with increased risk of ischemic stroke
Data Sources: All relevant human-subject and English-language
studies in MEDLINE, EMBASE, and Science Citation Index
from January 1970 through February 2005
Study Selection and Data Extraction: All published studies of OC
or estrogen with any type of stroke as an outcome were included.
Studies were excluded if they included populations at high risk
for ischemic stroke or did not include low-dose OC use, ischemic
stroke, or a control group.
Data Synthesis: A meta-analysis of the nine included studies
showed positive association between current low-dose OC use
and ischemic stroke (Overall pooled odds ratio [OR], 2.1; 95%
confidence interval [CI], 1.7 - 2.7). Compared to never users,
current users had slightly higher risk (OR, 1.2; 95% CI, 0.4 3.2) and former users had significantly lower risk (OR, 0.6; 95%
CI, 0.5 - 0.7). Current users of second and third generation OC
had 2.4 times (95% CI, 2.0 - 3.0) and 2.0 times (95% CI, 1.3 3.0) increased risk of ischemic stroke, respectively, compared to
former or never users. The independent effect of low-dose OC
use on the risk of ischemic stroke was stronger among women less
than 35 years, nonsmokers, and normotensive women.
Conclusion: Current use of low-dose OC compared to former or
never use is associated with about two times increased risk of
ischemic stroke. However, considering its health benefits and
effectiveness of birth control and very low incidence of ischemic
stroke in young women, use of low-dose OC is generally safe.

1. Department of Medicine, Thomas Jefferson University,
Philadelphia, PA
2. Welch Center for Prevention, Epidemiology, and Clinical
Research, Department of Epidemiology, Johns Hopkins
Bloomberg School of Public Health, Baltimore, MD
3. Department of Physical Medicine and Rehabilitation, Johns
Hopkins University, Baltimore, MD
4. Department of Neurology and Neurosurgery, Johns Hopkins
University, Baltimore, MD
5. Sidney Kimmel Comprehensive Cancer Center, Johns
Hopkins University, Baltimore, MD
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There are not many studies that examined the risk of ischemic
stroke among low-dose OC users. Although it seems that
reduction in estrogen content decreases the thrombogenicity of
OCs and lowers the risk of ischemic stroke, there is a
heterogeneity in the reported risk among studies.4-6 Some studies
reported small increase,5-8 whereas others reported no increase in
the risk of ischemic stroke.9,10 Considering the lack of feasibility
of conducting randomized controlled trials and only limited
number of observational studies showing inconsistent results, it is
important to summarize the findings from observation studies
and investigate possible reasons for this inconsistency. This will
provide useful information on potential health risk of OCs that
are currently used by over 76 million women worldwide.11
Here, we conducted a meta-analysis to evaluate existing evidences
to determine whether low-dose OC use is associated with increased
risk of ischemic stroke and to quantify this risk among subgroups
with different characteristics. Specifically, we included only
premenopausal women who comprise the majority of OC users.
The exposure was confined to the use of OCs containing less than
50 _g of estrogen that are currently in widespread use. The
outcome was limited to ischemic stroke, because the strength of
association between OC use and hemorrhagic stroke is not strong.12
We reviewed all relevant cohort studies and case-control studies
that were conducted in the Unites States as well as internationally.

Methods
Study Selection
We conducted a literature search using MEDLINE, EMBASE, and
Science Citation Index (January 1970 through February 2005 ).
The following key words and subject terms were used: (intracerebral
hemorrhage OR venous sinus thrombosis OR cerebral infarct OR
cerebral ischemia OR cerebrovascular accident OR cerebrovascular
disease OR stroke) AND (oral contraceptive OR birth control pill
OR estrogen). The search was restricted to English and humans.
The original search yielded 1183 citations from MEDLINE, 730
from Science Citation Index, and 132 from EMBASE (excluding
duplicates from MEDLINE), for a total of 2045 citations.

Articles

restricted our analysis to the articles published since 1985, which
left 55 articles for full-text review. The 55 articles identified
during the literature search were reviewed by an investigator (who
initially had not reviewed the abstract of the article in question)
who reassessed the article and discussed the reasons for inclusion
or exclusion with the rest of the investigators. From the 55 articles,
we excluded 6 studies because of the inclusion of postmenopausal
women without stratification, 4 because of fatal stroke or
hemorrhagic stroke as the only outcome, 5 because of duplicate
publications using the same data, and 10 because of the lack of
comparison group (case series only). Ten articles were excluded,
because they were published as abstracts only, review articles,
letters to editor, or editorials and did not contain enough
information for the analysis. We also exclude 11 studies that were
conducted before 1990 and did not specify estrogen dose. Finally,
data from nine remaining studies were abstracted for our analysis
(See Figure 1). There were no randomized controlled trials or
cohort studies that satisfied our criteria.

Data Abstraction

Figure 1. Retrieval of Eligible Studies
A preliminary title review was done by five investigators and 377
potentially eligible articles were selected for abstract review. Each
abstract was reviewed independently by two investigators, with
the following exclusion criteria:
1. hormone replacement therapy,
2. inclusion of postmenopausal women without stratification,
3. subarachnoid or subdural hemorrhage as the only primary
outcome,
4. estrogen dose exclusively more than 50 mg (first generation
OCs) or dose not specified or progesterone-only contraceptives,
5. stroke not as a primary outcome,
6. women with coagulation disorders,
7. case series without controls, and
8. recurrent stroke.
With these exclusion criteria, we excluded 277 articles.
Considering the time when high-dose OCs were withdrawn from
the market and low-dose OCs became widely available, we further

Data were abstracted by the reviewers of each study and verified
by the rest of the investigators. Any disagreements were resolved
through full discussion. Information on study quality as well as
data was collected. Years of study conducted, study region, type
of control (hospital or population control), age distribution of
participants, and numbers of case and control were abstracted.
Outpatient control was considered as hospital control. Definition
of current OC users varied among studies and we followed the
definition used by individual studies. Non-current users were
defined as both former and never users. Estrogen dose was defined
as low-dose, either when an OC contained less than 50 _g of
estrogen or when it belonged to second or third generation. The
generation of OCs was determined by estrogen dose and types of
progesterone7. Although the definition of generation was not
consistent among studies, estrogen dose in each generation was
consistent among studies (50 _g or more for first generation, 3040 _g for second generation, and 20-30 _g for third generation)
and we followed the classification used by each study. Estrogen
dose or generation of OCs was abstracted from each study when
it was mentioned in the article. When it was not mentioned, it
was estimated from the prevailing use pattern in the study area
during the study period. Generally, the estrogen dose was assumed
to be less than 50 _g if a study was conducted after 1990. When
a study was conducted before 1990 and did not specify the
estrogen dose or generation of OCs, it was excluded from our
analysis. Information on exposure to OCs (current, past, or never
use) was obtained. Information on definition of stroke and
diagnostic methods, such as use of clinical or radiographic
diagnosis or both, was gathered. We excluded hemorrhagic stroke,
such as subarachnoid, intracranial, and intraparenchymal
hemorrhage. Refusal rate was calculated separately for cases and
controls as the percentage of eligible individuals who declined to
participate in a study.
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Table 1. Characteristics of Nine Eligible Case-Control Studies for Data Abstraction
Source
(Year)
Lidegaard
et al. (1993)
Petitti et al.
(1996)
WHO
Collaborative
(1996)
Barinagarrementeria et al.
(1998)
Heinemann
et al. (1998)
Chang et al.
(1999)
Kemmeren
et al. (2002)
Lidegaard
et al. (2002)
Nightingale
et al.* (2004)

Region
Denmark
US
International

Mexico

Europe

Years
of Study
19851989
19911994
19891993

Control
Type
P

Age
(Years)
15 - 44

P

15 - 44

H

15 - 49

19871998

H

19931996
Europe
19901994
Netherlands 19901995
Denmark
19941998
UK
19921998

Case/
Control#
320 /
1197
295 /
774
697 /
1952

Estrogen
Dose (_g)
≥50,
30-40, 20
<50

Exposure
Assessment
Questionnaire

Stroke
Type
Ischemic

Stroke
Diagnosis
Clinical

Interview

≥50, <50

Interview

Ischemic
Clinical
Hemorrhagic
Ischemic
Clinical

13.7% / NS

11 - 40

130 /
122

NS

NS

Ischemic

Clinical
Radiologic

NS / NS

P, H

16 - 45

≥50, <50

Interview

Ischemic

20 - 44

≥50, <50

Interview

Ischemic

P

19 - 49

≥50, <50

Questionnaire

Ischemic

P

15 - 44

Questionnaire

Ischemic

P

15 - 49

≥50,
30-40, 20
NS

Clincial
Radiologic
Hemorrhagic
Clinical
Clinical
Radiologic
Clinical

NS / NS

H

220 /
775
291 /
736
203 /
916
609 /
3946
187 /
1129

UK GPRD

Ischemic

Clinical
Radiologic

Case/Control
Refusal Rate (%)
2.2% / 0.1%
9.6% / N

NS / NS
31% / 27%
2.2% / 0.5%
NS / NS

Abbreviations: WHO, World Health Organization; P, population controls; H, hospital controls; NS, not specified; HTN, hypertension; DM,
diabetes mellitus; BMI, body mass index; RHD, rheumatic heart disease; FH, family history; OC, oral contraceptive; UK GPRD, UK General
Practice Research Database
* Nested case-control study using the UK General Practice Research Database`

Risk estimates used in our meta-analysis were determined a priori.
For the primary analysis, the odds ratio (OR) comparing current
with non-current users after adjusting for potential confounders
was chosen and pooled. Standard errors were calculated from
adjusted odds ratios and their 95% confidence intervals (CIs).
Information about potential confounders that were adjusted for
in individual studies was also collected. When a study did not
provide the adjusted odds ratio or its 95% CI comparing current
with non-current users, we excluded the study from the analysis4.
In subgroup analyses, we dichotomized age as 35 years or more
vs. less than 35 years, smoking as current vs. non-current smokers,
and hypertension as present vs. absent. Then we collected the data
relevant to ischemic stroke from each stratified analysis.

Statistical Analysis
We combined the odds ratios (ORs) comparing current with noncurrent users from each study using both fixed-effects model and
DerSimonian and Laird random-effects model13. However, results
from the random-effects model are presented in this report because
significant heterogeneity was identified among studies. In the four
studies5-8 that provided adjusted ORs for each generation of OCs,
we combined the adjusted ORs for second and third generations
using the random effects model. In a study14 that had stratification
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by presence or absence of migraine, overall adjusted OR was
calculated in a similar fashion. A forest plot was created using
adjusted ORs and 95% CIs from each study. One study4 that did
not provide the adjusted OR of ischemic stroke comparing current
with non-current users was not included when calculating overall
OR, but included in other analyses. Heterogeneity among studies
was calculated using chi-square test and studies were defined as
heterogeneous when p-value was less than 0.05.
Preplanned subgroup analyses were performed according to
exposure classification (current vs. never users and former vs.
never users), progesterone type (second generation, third
generation, and second vs. third generation), and presence or
absence of other risk factors for ischemic stroke (≥ 35 years old
vs. < 35 years old, smokers vs. non-smokers, and hypertensives vs.
normotensives). To evaluate which study characteristics
contributed to the heterogeneity, we examined the influence of
study characteristics on overall OR by applying different inclusion
criteria. In addition, the influence of each study was evaluated by
eliminating each study at a time and calculating the resultant
overall OR after the study was excluded. To examine the presence
of publication bias, Egger’s test and Begg’s test were performed
and a funnel plot was plotted. All statistical analyses were
performed using STATA 8.2.

Articles

Results

Quantitative Analysis

Qualitative Analysis

The overall pooled OR for ischemic stroke comparing current
with non-current users calculated by the random-effects model
was 2.14 (95% CI, 1.69 - 2.72) (Figure 2). Significant
heterogeneity was observed among studies (P = 0.02).

The characteristics of nine case-control studies that satisfied our
criteria were summarized (Table 1). Among the selected studies,
six4, 6-8,14,15 were conducted in Europe, one9 in the US, one16 in
Mexico, and one5 in Europe and developing countries in Asia,
Africa, and Latin America. Three studies5,7,14 involved participants
from more than one country. All the studies were conducted since
1985 and published since 1993. Five studies4,6,8,9,15 used population
control, three5,14,16 used hospital control, and one7 used both. Age
distribution of study subjects ranged from 11 to 49 years old. The
number of cases varied from 130 in the study by
Barinagarrementeria et al16 to 697 in the study by World Health
Organization (WHO) collaborative.5 There was only one study9 in
which estrogen dose in OCs was exclusively less than 50 _g. Six
studies4-8,14 reported both estrogen dose less than 50 _g and greater
than 50 _g. Two studies15,16 did not state estrogen dose explicitly. As
for the study outcome, seven studies4-8,15,16 reported ischemic stroke
and two studies9,14 reported both ischemic and hemorrhagic stroke.

In the subgroup analysis by exposure classification, there was weak
evidence that current users were associated with increased risk of
ischemic stroke compared to never users (OR, 1.18; 95% CI, 0.44
- 3.16) (See Table 2). In contrast, former users were associated
with decreased risk compared to never users (OR, 0.58; 95% CI,
0.48 - 0.71). By progesterone type, second generation was
associated with 2.41 times increased risk of ischemic stroke (OR,
2.41; 95% CI, 1.96 - 2.96) and third generation was associated
with 1.98 times increased risk (OR, 1.98; 95% CI, 1.29 - 3.03).
Third generation OCs seemed to be associated with less increase
in risk compared to second generation, but there was little
difference between the two formulations in direct comparison.
Test of heterogeneity was not significant among studies pooled
for current vs. never users and for third generation OCs.

Several methodological issues were examined. In most studies,
exposure to OCs was measured by mailing questionnaires4,6,8 or
personal interviews.5,7,9,14 One study16 did not report how they
obtained the information on OC exposure and one study15 used
General Practice Research Database which is an automated
national database collected for research purpose and contains
medical and prescribing records for more than 8.5 million people
throughout the UK. With regard to outcome ascertainment, four
studies7,8,15,16 used a combination of clinical and radiological
diagnosis, whereas five studies4-6,9,14 used only clinical diagnosis.

Current use of low-dose OCs was associated with 1.2 times
increase in risk of ischemic stroke among women of 35 years or
older (OR, 1.20; 95% CI, 0.19 - 7.56) and 1.48 times increase
among women less than 35 years (OR, 1.48; 95% CI, 0.77 2.83). Non-smokers who currently use OCs (OR, 2.60; 95% CI,
1.49 - 4.54) seemed to have higher risk of ischemic stroke than
smokers (OR, 2.09; 95% CI, 1.68 - 2.59). Similarly, increase in
risk of ischemic stroke related to OC use was greater among
normotensive women (OR, 2.55; 95% CI, 1.50 - 4.32) than
among hypertensive women (OR, 0.71; 95% CI, 0.22 - 2.31).

Cases and controls were matched for age in eight studies.4-7,9,14-16
Age was adjusted in three studies6-8 and socioeconomic status was
adjusted in two studies.6,14 Smoking was adjusted in eight studies49,14,15
and hypertension was adjusted in seven studies.5,7-9,14,15 Four
studies7-9,15 adjusted for diabetes. The study by Lidegaard et al6
controlled for hypertension and diabetes in their initial model,
but excluded them from the final model because of lack of
confounding influence by the variables. The study by
Barinagarrementeria et al16 did not provide any information on
potential confounders that they adjusted for (Figure 2).

The findings from the analysis examining the influence of study
characteristics on overall pooled OR were presented (Table 3).
When we included four studies that used radiographic imaging
for the diagnosis of stroke, the pooled OR changed from 2.14 to
2.45. The combined OR was 2.81 when the studies with
population control were all excluded, whereas it was 1.89 when
the studies with hospital control were all excluded. Significant
heterogeneity was observed only when the studies that did not
report estrogen dose were excluded.

All of the studies except for one study4 reported adjusted OR
comparing current with non-current users. Adjusted OR comparing
current with never users was provided in two studies4,9 and adjusted
OR comparing ever vs. never users was provided in one study.9
There were three studies7-9 reporting OR by smoking, two studies8,9
reporting OR by age, four studies5-8 reporting OR by the
generation of OCs, three studies7-9 reporting OR by history of
hypertension, and one study14 reporting OR by history of migraine.
The definition of exposure to OCs was inconsistent among
studies. Current OC use was defined as the use of OCs within 1
month up to 1 year.

Sensitivity Analysis
The influence of each study on overall OR was examined (Figure
3). The study published in 2002 by Lidegaard et al6 had moderate
influence on overall OR. Overall OR after omitting the study by
Lidegaard et al6 was 2.42 (95% CI, 1.98 - 2.94). Omission of
other studies made little difference.

Publication Bias
The possibility of publication bias was evaluated by using the Egger’s
test (weighted regression) and Begg’s test (rank correlation method).
P-value for bias in the Egger’s test was 0.62 and p-value in Begg’s
test was 0.75. A funnel plot showed symmetry around the overall
pooled OR, indicating the absence of publication bias (Figure 4).
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Figure 2. Overall Odds Ratio Comparing Current vs. Non-current Users for Ischemic Stroke and 95% Confidence Intervals (CIs)*
Study (Year)
Pettiti (1996)
WHO-Europe (1996)
WHO-Developing (1996)
Barinagarrementeria (1998)
Heinemann (1998)
Chang (1999)
Kemmeren (2002)
Lidegaard (2002)
Nightingale (2004)
Overall Odds Ratio
Test for Heterogeneity, P-value: 0.02

Overall Odds Ratio
(95% CI)
1.18 (0.54 - 2.58)
1.53 (0.71 - 3.28)
3.26 (2.20 - 4.82)
2.50 (1.12 - 5.58)
2.77 (2.02 - 3.79)
2.25 (0.44 - 11.45)
2.17 (1.52 - 3.09)
1.61 (1.32 - 1.96)
2.30 (1.16 - 4.57)
2.14 (1.69 - 2.72)

Controlled for
Age
Race
+
NS
NS
+
+
+
-

SES
NS
+
+
-

Smk
+
+
+
NS
+
+
+
+
+

HTN
+
+
+
NS
+
+
+
+

DM
+
NS
+
+
+

Abbreviations: WHO, World Health Organization; SES, social economic status;
Smk, smoking; HTN, hypertension; DM, diabetes mellitus, NS, non specified
* Lidegaard et al. (1993) was not included in calculating overall odds ratio, because it did not provide the odds ratio comparing current vs.
non-current users. Two components of WHO collaborative (1996) - Europe vs. Developing countries (Asia, Africa, and Latin America) were
considered separately.

Table 2. Pooled Odds Ratios and 95% Confidence Intervals (CIs) of Ischemic Stroke from Stratified Meta-analyses*
Data Stratifications

Number of Studies Pooled
(References)†
9 (4, 5, 6, 7, 8, 9, 14, 15, 16)

All studies
Exposure classification
Current vs. Never users
2 (4,
Former vs. Never users
2 (4,
Progesterone type
2nd generation
5 (5,
3rd generation
5 (5,
3rd vs. 2nd generation
2 (7,
Independent effect of oral contraceptive use among:
≥ 35 years old
2 (8,
< 35 years old
2 (8,
Smokers
3 (7,
Non-smokers
3 (7,
HTN present
2 (7,
HTN absent
3 (7,

Pooled
Odds Ratio (95% CI)
2.14 (1.69 - 2.72)

Test for Heterogeneity
P-value
0.02

9)
9)

1.18 (0.44 - 3.16)
0.58 (0.48 - 0.71)

0.06
0.55

6, 7, 8)
6, 7, 8)
8)

2.41 (1.96 - 2.96)
1.98 (1.29 - 3.03)
1.12 (0.76 - 1.64)

0.33
0.07
0.63

9)
9)
8, 9)
8, 9)
8)
8, 9)

1.20
1.48
2.09
2.60
0.71
2.55

0.06
0.71
0.33
0.14
0.06
0.08

(0.19
(0.77
(1.68
(1.49
(0.22
(1.50

-

7.56)
2.83)
2.59)
4.54)
2.31)
4.32)

Abbreviation: HTN, hypertension
* Pooled odds ratios are comparing current vs. non-current oral contraceptive users, except for those under exposure classification.
† The study by WHO collaborative5 was counted as two separate studies (Europe and developing countries).
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Discussion
In our meta-analysis, all the nine studies showed positive
association between current low-dose OC use and ischemic stroke
and six of them had statistically significant association. The overall
pooled OR of ischemic stroke among current low-dose OC users,
compared with non-current users, was 2.14 (95% CI, 1.69 - 2.72)
(Figure 2). Therefore, our meta-analysis suggests that low-dose
OC use is a risk factor for ischemic stroke.
Among the nine included studies, the study published in 1993 by
Lidegaard et al4 was not included when calculating overall OR,
because the authors did not report the standard error or 95% CI
associated with the adjusted OR of 3.46 comparing current with
non-current users. The study by WHO collaborative5 had two
distinct components - Europe and developing countries including
Asia, Africa, and Latin America - showing different results and it
was considered as two different studies. The studies by
Barinagarrementeria16 and Nightingale15 were included despite the
lack of information on estrogen dose, because the dose was
estimated to be less than 50 _g considering the region and years
of study. During the literature search, we found three cohort
studies,17-19 but they did not meet our criteria. One cohort study
by Stampfer et al17 was conducted from 1976 through 1984 and
did not have information on estrogen dose. Considering the time
period when it was conducted, we suspected that it had included
a significant proportion of high-dose OC users. The other two
cohort studies that were conducted from 1980 through 1982 by
Porter et al18 and from 1968 through 1994 by Mant et al19
reported only proportion of low-dose OC users without stratified
results. High-dose OC users consisted of 59% in the study by
Porter et al18 and over 32% in the study by Mant et al.19 We were
unable to extract the data related to low-dose OC use from the
three cohort studies. They were not included in the analysis,
because including significant proportion of high-dose OC users
will overestimate the risk of ischemic stroke.
Significant heterogeneity was observed when we combined all the
studies to obtain the overall pooled OR (P = 0.02). It is because all
the included studies are case-control studies of varying qualities
and characteristics. They are particularly susceptible to
confounding and bias, compared to cohort studies and randomized
controlled trials.20 Each study recruited participants at variable risk
by applying different inclusion and exclusion criteria and used
different methods for assessing exposure and ascertaining outcome.
Thus, we used the DerSimonian and Laird random-effects model
to encompass non-random variation between study results and
allow more conservative CI for the overall OR.13 Residual
confounding always exists in a meta-analysis of observational
studies. Some studies did not measure or control for important
risk factors for ischemic stroke, such as age, smoking, hypertension,
and diabetes (Figure 2). In addition, there are several potential
sources for bias in case-control studies. Information on past

exposure to OCs relies on participants’ recall and the extent of
recall between cases and controls tends to be different, leading to
biased results. The studies by Lidegaard et al4, 6 and Kemmeren
et al8 mailed questionnaires to participants, whereas the studies by
Petitti et al9, WHO collaborative5, Heinemann et al7, and Chang
et al14 used personal interviews based on standardized questionnaires. The accuracy of information collected by these methods
varies among studies and is a source of information bias. Only
Nightingale et al15 used a reliable database that has medical and
prescribing records collected for research purpose. Classification of
exposure to OCs was also inconsistent between studies. Differential
refusal to participate in the study between cases and controls may
indicate the presence of selection bias.
We performed subgroup analyses to examine how the association
between low-dose OC use and risk of ischemic stroke changes
according to exposure classification, progesterone types, and
women with different risk factors for ischemic stroke (Table 2).
Compared to never users, current users seemed to have slightly
higher risk (OR, 1.18; 95% CI, 0.44 - 3.16) and former users
had significantly lower risk (OR, 0.58; 95% CI, 0.48 - 0.71).
Decreased risk in former users was consistent between studies.
Possible explanation is that never users may have multiple risk
factors and are at higher risk for ischemic stroke than users.
Women who stopped taking OCs may be more health-conscious
and have a reduced risk due to healthier lifestyle. Past use does
not seem to have a long term “hangover” effect. Different
progesterone formulation in OCs was also associated with
different risk of ischemic stroke. This may be due to the effect of
different progesterone components, different risk profiles between
users of second generation and users of third generation, or
preference of prescribing physicians between studies in different
countries. Thus, it is possible to underestimate or overestimate
the risk of ischemic stroke associated with third generation OC
use. The independent effect of low-dose OC use on the risk of
ischemic stroke was stronger among women less than 35 years
compared to women of 35 years or older, nonsmokers compared
to smokers, and normotensive women compared to hypertensive
women. These results are not consistent with recent meta-analyses
by Gillum et al21 and Chan et al12 and some studies7, 19, 22 that
suggested greater risk among OC users with additional risk factors
for ischemic stroke. Because only small number of the selected
studies reported stratified information on risk factors, the pooled
estimates from our subgroup analyses are less precise, which may
explain the inconsistency with previous reports.
To find out which study characteristics contributed to the
heterogeneity, we examined the influence of certain study characteristics on the pooled OR (Table 3). When we only included the
studies that used combination of clinical and radiological
diagnosis, the overall OR was 2.45 (95% CI, 1.99 - 3.06) and
test of heterogeneity was insignificant. Exclusion of two studies
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Figure 3. Influence of Each Study on Overall Odds Ratio
Meta-analysis
(exponential form)
Pettiti
WHO-Europe
WHO-Developing
Barinagarrementeria
Heinemann
Chang
Kemmeren
Lidegaard
Nightingale

Random-effects

(1996)
(1996)
(1996)
(1998)
(1998)
(1999)
(2002)
(2002)
(2004)

that did not report estrogen dose made very little change in the
overall OR and heterogeneity. Studies with population control had
much lower pooled OR than studies with hospital control,
meaning that control subjects from hospital underreported or less
frequently used OCs for some reasons. We also evaluated the
influence of each study on the overall OR by eliminating each
study at a time (Figure 3). Although the study by Lidegaard et al6
appeared to have moderate influence, there was not one particular
study that has significant influence on the overall OR.
A meta-analysis by Gillum et al21 on this topic reported in
subgroup analyses that low-dose OC use is associated with about
two times increased risk of ischemic stroke (Relative risk, 2.04;
95% CI, 1.51 - 2.76). Another recently published meta-analysis
by Chan et al12 also reported 2.7 times increase in risk for
thrombotic stroke associated with low-dose OC use (OR, 2.74;
95% CI, 2.24 - 3.35 ). However, Chan et al12 included the studies
that did not have information on estrogen dose and their primary
outcome was not confined to ischemic stroke. Our finding of 2.1
times increase (OR, 2.14; 95% CI, 1.69 - 2.72) is consistent with
their findings.
This meta-analysis has several limitations. As mentioned above, a
meta-analysis of observational studies has methodological
limitations and susceptibility to bias and confounding, leading to
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imprecise estimate of true association. We limited our analysis to
the studies in which the exposure and outcome were clearly stated
as low-dose OC and ischemic stroke, respectively. Therefore, only
nine studies were included. This small number substantially
limited our subgroup analyses and yielded less precise 95% CIs.
Due to the small number, we could not conduct a meta-regression
to assess risk of ischemic stroke related to low-dose OC use
controlling for several study-level covariates. In addition, we could
not investigate the dose-response relationship between low-dose
OC use and ischemic stroke, because most of studies did not
report the duration of OC use. As a result, potential biases and
confounders were not adequately addressed and reasons for
heterogeneity between studies were not sufficiently examined.
Presently, more than 10 million women in the United States and
more than 76 million worldwide use OCs.11 Our meta-analysis
found that current use of low-dose OC increases the risk of
ischemic stroke approximately by two times. However, when we
consider its health benefits and effectiveness of birth control and
very low baseline incidence of ischemic stroke in young women
of less than 10 per 100,00023, low-dose OC use in
premenopausal women is generally acceptable and safe. Future
research is warranted to identify high-risk groups for ischemic
stroke associated with low-dose OC use and to investigate the
dose-response relationship between the exposure and outcome. ■
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Table 3. Influence of Study Characteristics on Overall Odds Ratios and 95% Confidence Intervals (CIs) of Ischemic Stroke*
Data Stratifications
All studies
Studies that used radiologic
imaging for diagnosis of stroke
Studies that reported estrogen dose
Studies that used
Hospital control
Population control

Number of Studies Pooled
(References)†
9 (5, 6, 7, 8, 9, 14, 15, 16)
4 (7, 8, 15, 16)

Pooled
Odds Ratio (95% CI)
2.14 (1.69 - 2.72)
2.45 (1.99 - 3.06)

Test for Heterogeneity
P-value
0.02
0.78

7 (5, 6, 7, 8, 9, 14)

2.10 (1.59 - 2.78)

0.01

5 (5, 7, 14, 16)
5 (6, 7, 8, 9, 15)

2.81 (1.83 - 4.30)
1.89 (1.52 - 2.35)

0.22
0.20

* Pooled odds ratios are comparing current vs. non-current oral contraceptive users, except for those under exposure classification.
† The study by WHO collaborative5 was counted as two separate studies (Europe and developing countries).
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THE SPECTRUM OF ADVANCED LIVER
DISEASE IN A TERTIARY CARE INSTITUTION
Kuntal M. Thaker, MD, Kuldip S. Banwait, MD, Maya Spodik, MD,
Steven K. Herrine, MD and Victor Navarro, MD
Purpose
In population based studies, the rise of HCV infection has
surpassed alcoholic liver disease (ALD) as the most common cause
of chronic liver disease. However, it is unknown if HCV is
becoming the dominant cause of advanced liver disease. The aim
of this study was to determine the distribution of etiologies in a
cohort of patients presenting with advanced liver disease.

Methods
A retrospective review of patients presenting with advanced liver
disease defined as the presence of endoscopically identified
esophageal or gastric varices for the period between January 1999
and December 2002. Etiologies of hepatic injury were identified
from the clinical record and laboratory database. Patients were
excluded if their disease could be attributed to more than one
cause (i.e. alcohol and HCV) or had a non-hepatic cause of portal
hypertension. Patients were grouped according to etiology: 1)
HCV, 2) ALD, 3) hepatitis B (HBV), or 4) other (cryptogenic
cirrhosis, non-alcoholic fatty liver disease, autoimmune hepatitis,
portal vein thrombosis).
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Results
A total of 411 patients were identified as having either esophageal
and/or gastric varices. The mean age was 56.1 years (range 1989). There were 275 males (66.9%) and 136 females (33.1%).
The proportions of females in those with HCV and ALD were
similar although women were predominant in non-viral, nonalcohol related disease group compared to other diagnoses (59.4%
vs. 24.3%, p<0.0001). Etiology of liver disease differed in those
older than 65 years of age compared to younger patients for all
diagnostic categories (p<0.0001) with ALD being more prevalent
than HCV in older patients (p=0.0120). Race was evenly
distributed amongst groups. Hepatitis C represented the single
most common etiology (42.1%) followed by alcohol (29.9%),
other predominantly non-viral, non-alcohol diagnoses (20.0%),
and hepatitis B (8.0%).

Conclusion
Etiology of liver disease drastically differs in those older than 65
years of age compared to younger patients. Higher prevalence of
ALD rather than HCV in elderly population alludes to different
risk behavior pattern between the two groups (i.e., intravenous
drug use more common in younger patients). For patients
younger than 65 years of age, HCV is the major cause of cirrhosis
and burden of complications of cirrhosis attributable to HCV
infection should be expected to rise as this population ages.
■
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